

HEALTH ANNUAL STATEMENT

AS OF DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

Aetna Health of Iowa Inc.

NA	IC Group Code0001 (Current)	0001 NAIC Company Co	de <u>95241</u> Employer	's ID Number42-1244752
Organized under the Laws o			State of Domicile or Port of	Entry IA
Country of Domicile		United States	of America	
Licensed as business type:		Health Maintenan	ce Organization	
Is HMO Federally Qualified?	Yes[] No[X]			
Incorporated/Organized	02/07/1985		Commenced Business	01/01/1986
Statutory Home Office	6165 NW 86th Stree			Johnston, IA, US 50131
	(Street and N	umber)	(City	or Town, State, Country and Zip Code)
Main Administrative Office		6165 NW 86 th Str (Street and		
	Johnston, IA, US 50131	(Street and	Number)	800-872-3862
(City c	r Town, State, Country and Zip	Code)		(Area Code) (Telephone Number)
Mail Address	151 Farmington Avenue	, RT21		Hartford, CT, US 06156
	(Street and Number or P	.O. Box)	(City	or Town, State, Country and Zip Code)
Primary Location of Books a	nd Records	6165 NW 86th S	treet, Suite 114	
		(Street and	Number)	000 070 0000
(City o	Johnston, IA, US 50131 r Town, State, Country and Zip (Code)		800-872-3862 (Area Code) (Telephone Number)
Internet Website Address	· · · · ·	www.aet	na.com	
Statutory Statement Contact	Ki	m E. Roth		215-775-6508
		(Name)		(Area Code) (Telephone Number)
	StatutoryReporting@aetna.com			860-262-7767
	(E-mail Address)			(FAX Number)
		OFFIC	ERS	
President	James Benjamin Boyman	V	ice President and Secretary	Edward Chung-I Lee
		OTH	ER	
	nior Investment Officer #		III, Assistant Controller	Amy Christine Fletcher, Chief Financial Officer #
Peter Keller, A	ssistant Controller	Whitney Dorothy Lavoi Tracy Louise Smith, Vice	e, Assistant Controller President and Treasurer	Robert Joseph Parslow, Corporate Controller
				-
James Ben	jamin Boyrnan	DIRECTORS OI James Dean		Richard Noble Storna
	·····			
all of the herein described a statement, together with relat condition and affairs of the sa in accordance with the NAIC or regulations require differe Furthermore, the scope of this	ssets were the absolute propert ted exhibits, schedules and expla aid reporting entity as of the report Annual Statement Instructions ar nces in reporting not related to s attestation by the described offi	y of the said reporting entity, anations therein contained, ar rting period stated above, and d Accounting Practices and F accounting practices and prc cers also includes the related	, free and clear from any lie nnexed or referred to, is a fu d of its income and deduction Procedures manual except to ocedures, according to the corresponding electronic fili	reporting entity, and that on the reporting period stated above, ens or claims thereon, except as herein stated, and that this ill and true statement of all the assets and liabilities and of the ons therefrom for the period ended, and have been completed to the extent that: (1) state law may differ; or, (2) that state rules best of their information, knowledge and belief, respectively. Ing with the NAIC, when required, that is an exact copy (except by various regulators in lieu of or in addition to the enclosed
· A				
James B	enjamin Boyman		-	Edward Chung-I Lee
	President			Vice President and Secretary
State of Pennsylvania County of Montgomery				State of Connecticut County of Hartford
Subscribed and sworn to bef			S	Subscribed and sworn to before me this
4th day of Febrer	ary, 2022		-	day of, 2022
K	U			

NOTARY PUBLIC (Seal)

NOTARY PUBLIC (Seal)

Commonwealth of Pennsylvania - Notary Seal KIM E. ROTH, Notary Public Montgomery County My Commission Expires April 25, 2025 Commission Number 1141410

a. Is this an original filing? Yes [X] No []



HEALTH ANNUAL STATEMENT

i T

AS OF DECEMBER 31, 2021 OF THE CONDITION AND AFFAIRS OF THE

Aetna Health of Iowa Inc.

8	NAIC Group Code	0001 NAIC Company Co	ode 95241 Employer's	ID Number 42-1244752
Organized under the Law	s of lo	wa	State of Domicile or Port of Er	ntry IA
Country of Domicile		United States	of America	
Licensed as business type	9:	Health Maintenan	ce Organization	
Is HMO Federally Qualifie	d?Yes[] No[X]			
Incorporated/Organized _	02/07/1985		Commenced Business	01/01/1986
Statutory Home Office	6165 NW 86th Stree	et, Suite 114		Johnston, IA, US 50131
-	(Street and N		(City or	Town, State, Country and Zip Code)
Main Administrative Office			reet, Suite 114	
	Johnston, IA, US 50131	(Street and	Number)	800-872-3862
(Cit	y or Town, State, Country and Zip	Code)	(A	rea Code) (Telephone Number)
Mail Address	1E1 Fermination Avenue	DT04		
Mail Address	151 Farmington Avenue (Street and Number or P		(City or	Hartford, CT, US 06156 Town, State, Country and Zip Code)
Primary Location of Books		,	treet, Suite 114	
Thinking Ecolution of Dooks		(Street and		
	Johnston, IA, US 50131			800-872-3862
(Cit	y or Town, State, Country and Zip	Code)	(A	rea Code) (Telephone Number)
Internet Website Address		www.aet	na.com	
Statutory Statement Conta	act Ki	m E. Roth		215-775-6508
		(Name)		(Area Code) (Telephone Number)
	StatutoryReporting@aetna.com		<u> </u>	860-262-7767
	(E-mail Address)			(FAX Number)
		OFFIC		
President	James Benjamin Boyman	V	rice President and Secretary	Edward Chung-I Lee
		ОТН	ER	
	Senior Investment Officer #		III, Assistant Controller	Amy Christine Fletcher, Chief Financial Officer #
Peter Keller	Assistant Controller	Whitney Dorothy Lavoi Tracy Louise Smith, Vice	e, Assistant Controller	Robert Joseph Parslow, Corporate Controller
		macy Louise Simili, vice		
lamas 0	aniamin Dauman	DIRECTORS O		Distant Makin Olama
James B	enjamin Boyman	James Dean	Christensen	Richard Noble Sloma
all of the herein described statement, together with re condition and affairs of the in accordance with the NAI or regulations require diffe Furthermore, the scope of	I assets were the absolute proper lated exhibits, schedules and expl. said reporting entity as of the repor C Annual Statement Instructions ar rences in reporting not related to this attestation by the described offi	y of the said reporting entity, anations therein contained, ar rting period stated above, and d Accounting Practices and F accounting practices and pro cers also includes the related	, free and clear from any lien: nnexed or referred to, is a full a d of its income and deductions Procedures manual except to th ocedures, according to the be corresponding electronic filing	porting entity, and that on the reporting period stated above, s or claims thereon, except as herein stated, and that this and true statement of all the assets and liabilities and of the s therefrom for the period ended, and have been completed he extent that: (1) state law may differ; or, (2) that state rules st of their information, knowledge and belief, respectively, with the NAIC, when required, that is an exact copy (except various regulators in lieu of or in addition to the enclosed

James Benjamin Boyman President

State of Pennsylvania County of Montgomery

Subscribed and sworn to before me this

day of . 2022

NOTARY PUBLIC (Seal)

State of...... Connecticut County of..... Hartford

Subscribed and swom to before me this day of Februar

2022 ynthia Mentano

Edward Chung-I Lee

Vice President and Secretary

NOTARY PUBLIC (Seal)



a. Is this an original filing? Yes [X] No [] b. If no,

1. State the amendment number.....

2. Date filed

3. Number of pages attached.....

	AS	SETS			
		1	Current Year 2	3	Prior Year 4
			_	Net Admitted Assets	Net Admitted Assets
1.	Bonds (Schedule D)	Assets 20 412 211	Nonadmitted Assets	(Cols. 1 - 2) 20,412,211	
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0 .	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$	0	0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0 encumbrances)	0	0	0	0
5.	Cash (\$5, 169,813 , Schedule E - Part 1), cash equivalents		0		
5.	(\$				
	investments (\$0 , Schedule L - Part 2) and shoreterm	6 006 005	0	6 006 005	22 770 456
6.	Contract loans, (including \$0 premium notes)				
0. 7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				0
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				0
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$0 charged off (for Title insurers				
	only)	0	0	0	0
14.	Investment income due and accrued		0		
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection				
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$1, 114,865)	1,233,380	0	1,233,380	
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers			0 .	
	16.2 Funds held by or deposited with reinsured companies	0			0
	16.3 Other amounts receivable under reinsurance contracts				0
	Amounts receivable relating to uninsured plans			3, 144, 117	· · · · ·
	Current federal and foreign income tax recoverable and interest thereon			0 	0
	Net deferred tax asset Guaranty funds receivable or on deposit				74 , 157 0
19. 20	Electronic data processing equipment and software			0 0	0
20. 21.	Furniture and equipment, including health care delivery assets	0	0	0.	0
۷۱.	(\$	0	0	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0	0
23.	Receivables from parent, subsidiaries and affiliates	0	0	0	0
23. 24.	Health care (\$	746.490	0		
25.	Aggregate write-ins for other than invested assets				,
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)				
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts				
28.	Total (Lines 26 and 27)	31,982,456	13,113	31,969,343	59,708,364
	DETAILS OF WRITE-INS	, ,	,	, ,	, ,
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	-	0	0
2501.	Recoverable state premium taxes	0	0	0	
2502.	Guaranty fund assessments				
2503.	Recoverable of state income taxes		0	4,849	0
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	29,872	0	29,872	138,983

ASSETS

LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAPI		Current Year	·	Prior Year
		1	2	3	4
		O averaged	United	Tatal	Tatal
	20.041	Covered	Uncovered 	Total	Total
1.	Claims unpaid (less \$			4,372,591 71,692	
2.	Accrued medical incentive pool and bonus amounts				,
3.	Unpaid claims adjustment expenses.				
4.	Aggregate health policy reserves, including the liability of				
	\$5,558,787 for medical loss ratio rebate per the Public	F 04F 00F	0	F 04F 00F	F F00 000
	Health Service Act				
5.	Aggregate life policy reserves				0
6.	Property/casualty unearned premium reserves				0
7.	Aggregate health claim reserves				
8.	Premiums received in advance			24	
9.	General expenses due or accrued		0	1,945	
10.1	Current federal and foreign income tax payable and interest thereon				
	(including \$0 on realized capital gains (losses))		0		1,720,001
10.2	Net deferred tax liability			0	0
11.	Ceded reinsurance premiums payable			0	0
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated	25 320			22.067
14.	Borrowed money (including \$0 current) and				£2,007
14.					
	interest thereon \$0 (including				•
	\$0 current)			0	
15.	Amounts due to parent, subsidiaries and affiliates			1,127,413	1,054,971
16.	Derivatives			0	0
17.	Payable for securities	0	0	0	
18.	Payable for securities lending	0	0	0	0
19.	Funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$				
	reinsurers and \$				
20.	Reinsurance in unauthorized and certified (\$0)	, , ,		, , , , , , , , , , , , , , , , , , , ,	,
20.	companies	0	0	0	0
04					
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans		0	0	0
23.	Aggregate write-ins for other liabilities (including \$0				
	current)				
24.	Total liabilities (Lines 1 to 23)			11,629,281	
25.	Aggregate write-ins for special surplus funds	XXX	XXX	0	0
26.	Common capital stock	XXX	XXX	1,267,835	1,267,835
27.	Preferred capital stock			0	0
28.	Gross paid in and contributed surplus				
29.	Surplus notes				0
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)				
32.	Less treasury stock, at cost:				
	32.10 shares common (value included in Line 26				
	\$	XXX	XXX	0	0
	32.20 shares preferred (value included in Line 27				
	\$0)				
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	20,340,062	
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	31,969,343	59,708,364
	DETAILS OF WRITE-INS				
2301.	Abandoned property liability		0	1,015	4,017
2302.					
2303.					
2398.					.0
	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	1.015	0	1.015	4.017
		, -	\$, -	,
2598.	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001.					
3002.					
3003.					
	Summary of remaining write-ins for Line 30 from overflow page			0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN	Current Y		Prior Year
		1	2	3
		Uncovered	Total	Total
1. Men	nber Months	XXX		
2. Net p	premium income (including \$	XXX	43 676 966	31 627 791
	nge in unearned premium reserves and reserve for rate credits			
	-			
	for-service (net of \$			
	revenue			0
	regate write-ins for other health care related revenues			
	egate write-ins for other non-health revenues			
8. Tota	I revenues (Lines 2 to 7)	XXX		
	pital and Medical:	0 405 570	04 474 404	14,000,000
	pital/medical benefits			
	er professional services			
	ide referrals			
12. Eme	rgency room and out-of-area		2,240,637	1,232,480
	cription drugs			3, 107, 565
14. Aggr	egate write-ins for other hospital and medical	0	0	0
15. Incer	ntive pool, withhold adjustments and bonus amounts	0	(71,591)	(3, 143, 120)
16. Subt	otal (Lines 9 to 15)			
Less	S:			
17. Net r	reinsurance recoveries	0		
18. Total	I hospital and medical (Lines 16 minus 17)			
19. Non-	health claims (net)	0	0	0
	ns adjustment expenses, including \$			
	eral administrative expenses			
	ease in reserves for life and accident and health contracts (including \$0		, ,	,,
	crease in reserves for life only)	0	0	(80,450)
	I underwriting deductions (Lines 18 through 22)			
	underwriting gain or (loss) (Lines 8 minus 23)			
	investment income earned (Exhibit of Net Investment Income, Line 17)			
26. Net r	realized capital gains (losses) less capital gains tax of \$			
	nvestment gains (losses) (Lines 25 plus 26)	0		
28. Net g	gain or (loss) from agents' or premium balances charged off [(amount recovered			
\$	0) (amount charged off \$	0	0	0
29. Aggr	regate write-ins for other income or expenses	0	0	0
	income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus		4 000 070	40,004,700
	plus 28 plus 29)		4,282,976	
31. Fede	eral and foreign income taxes incurred	XXX		1,987,612
32. Net i	income (loss) (Lines 30 minus 31)	XXX	3,549,301	8,347,180
DET	AILS OF WRITE-INS			
0601		XXX		
0602		XXX		
0603		XXX		
0698. Sum	mary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699. Tota	Is (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701		XXX		
0702		XXX		
0703		XXX		
0798. Sum	mary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799. Tota	Is (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401				
1402				
1403				
1498. Sum	mary of remaining write-ins for Line 14 from overflow page	0	0	0
1499. Tota	Is (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901				
2902				
2903				
2998. Sum	mary of remaining write-ins for Line 29 from overflow page	0	0	0
2999. Total	ls (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	0	0

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year		
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$0	0	0
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets		
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus.	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	(30,000,000)	
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)	(26,469,731)	4, 176, 285
49.	Capital and surplus end of reporting period (Line 33 plus 48)	20,340,062	46,809,793
	DETAILS OF WRITE-INS		
4701.			
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

		1	2
		Current Year	Prior Year
	Cash from Operations	Ourient real	
1.	Premiums collected net of reinsurance	42 779 543	30 942 919
2.	Net investment income		
3.	Miscellaneous income	,	1, 102,070
3. 4.			32,135,798
	Total (Lines 1 through 3)		
5.	Benefit and loss related payments		
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		0
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		0
9.	Federal and foreign income taxes paid (recovered) net of \$0 tax on capital gains (losses)		166,613
10.	Total (Lines 5 through 9)	43,747,864	22,158,394
11.	Net cash from operations (Line 4 minus Line 10)	20,725	9,977,404
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		1,590,000
	12.2 Stocks		0
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		250,000
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		1,839,994
13.	Cost of investments acquired (long-term only):		1,000,004
15.	13.1 Bonds	7 811 1/6	2 488 300
	13.2 Stocks		
			_
	13.3 Mortgage loans		0
	13.4 Real estate		0
	13.5 Other invested assets		0
	13.6 Miscellaneous applications		0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	8,061,146	2,488,300
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	13,060,196	(648,306
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	0
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		1,133,834
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		(3,066,166
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(16,764,451)	6,262,932
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year		
	19.2 End of year (Line 18 plus Line 19.1)	6,006,005	22,770,456
Note: Si	upplemental disclosures of cash flow information for non-cash transactions:		

Note: Sup 20.0001.

...0

0

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		1	2	3	4	5	6	7	8	9	10
			Comprehensive	Medicare	Dental	Vision	Federal Employees Health	Title XVIII	Title XIX		Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1	Net premium income	43.676.966	.621,395	0	0	0	225.698	42.829.873	0	0	0
	Change in unearned premium reserves and reserve for rate credit	(504,933)	(450,471)			0	(54,462)		۔ ۱	0	0
3.	Fee-for-service (net of \$0	(001,000)									
4.	medical expenses)		U	U.		U			u	U.	XXX XXX
	Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	XXX					XXX	XXX	xxx	
7.				0		0			0	0	0
8.	Hospital/medical benefits		(197,858)	Q .	0	0	85		0	0	XXX
9.	Other professional services		(8, 144)	Q	0	0	0		0	0	XXX
10.	Outside referrals			Q	0	0	0		0	0	XXX
11.	Emergency room and out-of-area		(726)	0	0	0	0		0	0	XXX
12.	Prescription drugs			0	0	0	0	4,654,324	0	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	(71,591)		0	0	0	0		0	0	XXX
15.	Subtotal (Lines 8 to 14)		(377,937)	0	0	0			0	0	XXX
16.	Net reinsurance recoveries		0	0	0	0	0		0	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)		(377,937)	0	0	0			0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19.	Claims adjustment expenses including \$		(48,907)	0	0	0	o		ρ	0	0
20.	General administrative expenses			0	0	0	(164 , 685)	4, 185, 811	0	0	0
21.	Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)			0	0	0	(164 , 600)		0	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	3,555,244	338,473	0	0	0	335,836	2,880,935	0	0	0
0504	DETAILS OF WRITE-INS										
0501.											XXX
0502. 0503.											XXX
	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	
	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX		XXX	XXX	XXX	XXX	XXX	XXX	0
1301.											XXX
1302.											XXX
1303. 1398.	Summary of remaining write-ins for Line 13 from										XXX
	overflow page	0	۵	0	۵	٥	o	0	0	0	
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)		0	0	
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan		0	0	
6. Title XVIII - Medicare		0	400,478	
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)		0		
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	44,077,444	0	400,478	43,676,966

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
		Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
	Payments during the year:	04 004 007	(101.001)					05 040 400			
	1.1 Direct		(121,991)	0	0	0			0	0	0
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	1.3 Reinsurance ceded		0	0	0	0	0		0	0	0
	1.4 Net		(121,991)	0	0	0	85		0	0	0
	Paid medical incentive pools and bonuses	(103,561)	(154,271)	0	0	0	0		0	0	0
3.	Claim liability December 31, current year from Part 2A:										
	3.1 Direct	4,412,532		0	0	0	0	4,395,934	0	0	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	3.3 Reinsurance ceded		0	0	0	0	0		0	0	0
	3.4 Net	4,372,591		0	0	0	0	4,355,993	0	0	0
4.	Claim reserve December 31, current year from Part 2D:										
	4.1 Direct			0	0	0	0	0	0	0	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
	4.4 Net			0	0	0	0	0	0	0	0
5.	Accrued medical incentive pools and bonuses, current										
	year			0	0	0	0		0	0	0
6.	Net healthcare receivables (a)		(5,620)	0	0	0	0		0	0	0
7.	Amounts recoverable from reinsurers December 31,										
	current year	0	0	0	0	0	0	0	0	0	0
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct	4,015,882		0	0	0	0	3,923,506	0	0	0
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	8.3 Reinsurance ceded		0	0	0	0	0		0	0	0
	8.4 Net			0	0	0	0		0	0	0
9.	Claim reserve December 31, prior year from Part 2D:										
	9.1 Direct			0	0	0	0	0	0	0	0
	9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	9.3 Reinsurance ceded	.0	0	0	0	0	0	0	.0	0	0
	9.4 Net	.690		0	0	0	0	0	0	0	0
10.	Accrued medical incentive pools and bonuses, prior year	39,722	31,722	0	0	0	0	8,000	0	0	0
11.	Amounts recoverable from reinsurers December 31,	}	. /·		-			,	-		
	prior year	0	0	0	0	0	0	0	0	0	0
12.	Incurred Benefits:										ĺ
	12.1 Direct		(192,736)	0	0	0			0	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	346,508	0	0	0	0	0	346,508	0	0	0
	12.4 Net	34,654,467	(192,736)	0	0	0	85	34,847,118	0	0	0
13	Incurred medical incentive pools and bonuses	(71,591)	(185,201)	0	n N	0 0	00	113.610	0	n .	۰ ۱

(a) Excludes \$0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct			0	0	0	0	1,436,047	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	1,439,241		0	0	0	0	1,436,047	0	0	0
2. Incurred but Unreported:										
2.1 Direct			0	0	0	0	2,959,887	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded		0	0	0	0	0		0	0	0
2.4 Net	2,933,350	13,404	0	0	0	0	2,919,946	0	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	4,412,532		0	0	0	0	4,395,934	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded		0	0	0	0	0		0	0	0
4.4 Net	4,372,591	16,598	0	0	0	0	4,355,993	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	uring the Year	Claim Reserve a December 31		5	6
Line of Business	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)			8,138	8,563	(479,002)	
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan		0	0	0		0
6. Title XVIII - Medicare				4,310,968	2,118,817	3,913,709
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)				4,319,531	1,639,900	4,006,775
10. Healthcare receivables (a)	0		0	0	0	
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts		(118,622)				
13. Totals (Lines 9 - 10 + 11 + 12) (c) Evaluates $(1 - 10 + 11 + 12)$	1,601,798	32,126,074	53,855	4,390,531	1,655,653	3,589,382

(a) Excludes \$0 loans or advances to providers not yet expensed.

1

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumi	ulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018	XXX				
4. 2019	XXX				
5. 2020					
6. 2021	XXX	XXX	XXX	XXX	210

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021		
1. Prior	21,877	21,877					
2. 2017							
3. 2018							
4. 2019		XXX					
5. 2020		XXX	XXX				
6. 2021	XXX	XXX	XXX	XXX	219		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1	2017	209,641	166,343		0.0	166,343	79.3		Cxpenses	166,343	79.3
2	2017	32.328	21.843	0	0.0	21.843	67.6	0	0		67.6
3.	2019	5,595	5,273	0	0.0	5,273	.94.2	0	0		.2
4.	2020			0					0		
5.	2021	171	210	(47)	(22.4)	163	95.3	9	0	172	100.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

		Cu	mulative Net Amounts	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018					
4. 2019					
5. 2020					
6. 2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Medicare Supplen	nent						
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and E Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021		
1. Prior							
2. 2017							
3. 2018							
4. 2019		XXX					
5. 2020							
6. 2021	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ymer ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2	2018										
2.	2019										
3.											
4.	2020					·····					
5.	2021										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Dental Only

		Cu	mulative Net Amounts I	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior	0	0	0	0	0
2. 2017	0	0	0	0	0
3. 2018		0	0	0	0
4. 2019			0	0	0
5. 2020			XXX	0	0
6. 2021	XXX	XXX	XXX	XXX	0

Section B	 Incurred 	Health	Claims -	- Dental	Only
-----------	------------------------------	--------	----------	----------	------

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year							
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021			
1. Prior		11	11					
2. 2017	0	0	0	0	0			
3. 2018		0	0	0	0			
4. 2019		XXX	0	0	0			
5. 2020		XXX		0	0			
6. 2021	XXX	XXX	XXX	XXX	0			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1) Percent
were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2017	0	0			0	0.0	0	0		
 2. 2018	0	0			0	0.0	0	0		0.0
 3. 2019	0	0		0.0	0	0.0	0	0		0.0
4. 2020	0	0		0.0	0	0.0	0	0		0.0
 5. 2021	0	0	0	0.0	0	0.0	0	0	0	0.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Vision Only

		Cu	mulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018	XXX				
4. 2019	XXX	XXX			
5. 2020	XXX	XXX.			
6. 2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Vision Only					
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Outstanding at End of Year				
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018					
4. 2019					
5. 2020	XXX				
6. 2021	XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment	(Col. 3/2) Perc	Payments	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2017										
2.	2018										
3.	2019										
4	2020										
5.	2021										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

		Cu	mulative Net Amounts Pai	id	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017	0			17	17
3. 2018		0		0	0
4. 2019				0	0
5. 2020				0	0
6. 2021	XXX	XXX	XXX	XXX	0

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

	Sum of Cumulative N	et Amount Paid and Cla O	aim Liability, Claim Reserv utstanding at End of Year	ve and Medical Incentive P	'ool and Bonuses
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021
1. Prior					
2. 2017	0			19	19
3. 2018		0		0	0
4. 2019				0	0
5. 2020				0	0
6. 2021	XXX	XXX	XXX	XXX	0

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2017	0		0			.0.0	0	0		.0.0
2.	2018	(509)	0	0		0	.0.0	0	0	0	
3.	2019	(45)	0	0		0	.0.0	0	0	0	.0.0
4.	2020	875	.0	0	0.0	0	.0.0	0	.0	0	0.0
5.	2021	171	0	0	0.0	0	0.0	0	0	0	0.0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cu	mulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior	0	0	0	0	0
2. 2017	0	0	0	0	0
3. 2018					11
4. 2019			0	0	0
5. 2020					
6. 2021	XXX	XXX	XXX	XXX	31,916

Section B - Incurred Health Claims - Title XVIII								
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bo Outstanding at End of Year							
	1	2	3	4	5			
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021			
1. Prior	(2,939)	(2,939)	(2,939)	(2,939)	(2,939)			
2. 2017	11	11		11	11			
3. 2018	XXX	11		11	11			
4. 2019		XXX	0	0	0			
5. 2020		XXX						
6. 2021	XXX	XXX	XXX	XXX	36,298			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5 Claim and Claim	6	7	8	9 Total Claims and	10
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017		0	0		0	0.0	0	0	0	
2.	2018			0	0.0			0	0		0.0
3.	2019		0	0		0		0	0	0	0.0
4.	2020			0					0		
5.	2021	42,830	31,916	786	2.5	32,702	76.4	4,382	68	37,152	86.7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Title XIX

		Cu	mulative Net Amounts I	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018	XXX				
4. 2019	XXX	XXX			
5. 2020					
6. 2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Title XIX					
	Sum of Cumulative Ne	erve and Medical Incentiv	centive Pool and Bonuses		
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018	XXX				
4. 2019					
5. 2020	XXX	XXX	XXX		
6. 2021	XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ymen	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
	. 2017										
	. 2018										
	0040										
	. 2020										
4	. 2021										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Other

		C	Cumulative Net Amounts	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021
1. Prior					
2. 2017					
3. 2018	XXX				
4. 2019	XXX	xxx			
5. 2020					
6. 2021	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Other									
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Outstanding at End of Year								
	1	2	3	4	5				
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021				
1. Prior									
2. 2017									
3. 2018	XXX								
4. 2019		XXX							
5. 2020		XXX	XXX						
6. 2021	XXX	XXX	XXX	XXX					

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2017										
2.	2018										
3.	2019										
4.	2020										
5.	2021										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Grand Total

	Cumulative Net Amounts Paid					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2017	2018	2019	2020	2021	
1. Prior						
2. 2017						
3. 2018						
4. 2019						
5. 2020			XXX			
6. 2021	XXX	XXX	XXX	XXX	32,126	

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year					
Year in Which Losses Were Incurred	1 2017	2 2018	3 2019	4 2020	5 2021	
1. Prior						
2. 2017						
3. 2018	XXX					
4. 2019	XXX					
5. 2020	XXX	XXX				
6. 2021	XXX	XXX	XXX	XXX	36,517	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
-	1. 2017			0				0	0		
2	2. 2018			0				0	0		
3	3. 2019			0	0.0			0	0		
4	4. 2020			0	0.0				0		
Ę	5. 2021	43, 172	32,126	739	2.3	32,865	76.1	4,391	68	37,324	86.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	2	3	4	5	6	7	8	9
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other
1. Unearned premium reserves	0	0	0	0	0	0	0	0	
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	
3. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	
4. Reserve for rate credits or experience rating refunds (including									
\$0) for investment income		5,589,972	0	0	0			0	0
5. Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	
6. Totals (gross)		5,589,972	0	0	0			0	
7. Reinsurance ceded	0	0	0	0	0	0	0	0	
8. Totals (Net)(Page 3, Line 4)		5,589,972	0	0	0			0	
9. Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	
10. Reserve for future contingent benefits			0	0	0	0	0	0	
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	
12. Totals (gross)			0	0	0	0	0	0	
13. Reinsurance ceded	0	0	0	0	0	0	0	0	
14. Totals (Net)(Page 3, Line 7)	103	103	0	0	0	0	0	0	(
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	(
1101									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	(

(a) Includes \$ _____0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT PART 3 - ANALYSIS OF EXPENSES

		PART 3 - ANAL Claim Adjustme	YSIS OF EXPENSE ent Expenses	3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)	6,603				
2.	Salary, wages and other benefits			1,012,497	13	1,434,113
3.	Commissions (less \$0					
	ceded plus \$0 assumed)	0	0	1,140,604	0	1, 140,604
4.	Legal fees and expenses	0	4	21,407	0	21,411
5.	Certifications and accreditation fees	0	0	0	0	0
6.	Auditing, actuarial and other consulting services	0			2,751	470,398
7.	Traveling expenses		41	6,106	10	6,276
8.	Marketing and advertising	31			0	
9.	Postage, express and telephone				1	108 , 192
10.	Printing and office supplies	0				
11.	Occupancy, depreciation and amortization			(7,798)		
12.	Equipment	0	(1,482)		0	
13.	Cost or depreciation of EDP equipment and software		4,307			123,910
14.	Outsourced services including EDP, claims, and other services				1,385	
15.	Boards, bureaus and association fees			2,459	41	2,619
16.	Insurance, except on real estate				0	
17.	Collection and bank service charges	0				<u>6</u> ,018
18.	Group service and administration fees	0	0	0	0	0
19.	Reimbursements by uninsured plans	0	0	0	0	0
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	1	0		0	
22.	Real estate taxes	0	0		0	
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0	0		0	
	23.2 State premium taxes	0	0		0	
	23.3 Regulatory authority licenses and fees	0	0		0	
	23.4 Payroll taxes				0	
	23.5 Other (excluding federal income and real estate taxes)	0	0	1,212	0	1,212
24.	Investment expenses not included elsewhere	0	0	0		15,923
25.	Aggregate write-ins for expenses	24	9,528	14,656	0	24,208
26.	Total expenses incurred (Lines 1 to 25)			4,280,421		(a)5,054,940
27.	Less expenses unpaid December 31, current year .			1,945	0	70,058
28.	Add expenses unpaid December 31, prior year				0	234,602
29.	Amounts receivable relating to uninsured plans, prior year	0	0	1,395,413	0	1,395,413
30.	Amounts receivable relating to uninsured plans, current year	0	0	3,144,117	0	3,144,117
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	543,590	195,417	6,208,154	21,027	6,968,188
	DETAILS OF WRITE-INS					
2501.				(1,037)	0	(3)
2502.	Loss adjustment expense	0	(3)	14,488	0	14,485
2503.	Interest expense	0		1,205	0	9,727
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25	24	9.528	14,656	0	24,208
a) Inclu	above)des management fees of \$4,526,736 t		- / -	n-affiliates.	U	24,208

ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Aetna Health of Iowa Inc. EXHIBIT OF NET INVESTMENT INCOME

1		1	2
<u> </u>			Earned During Year
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax	(a)0	0
1.2	Other bonds (unaffiliated)	(a)709,340	
1.3	Bonds of affiliates	(a)0	
2.1	Preferred stocks (unaffiliated)	(b)0	0
2.11	Preferred stocks of affiliates	(b)0	0
2.2	Common stocks (unaffiliated)	0	
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans	(c)0	0
4.	Real estate		
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)9,600	
7	Derivative instruments		0
8.	Other invested assets	0	0
9.	Aggregate write-ins for investment income	6	6
10.	Total gross investment income	801,583	740,067
11.	Investment expenses		(g)21,027
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		(h)0
14.	Depreciation on real estate and other invested assets		(i)0
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		719,040
	DETAILS OF WRITE-INS		
0901.	Miscellaneous interest income		
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	6	6
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes \$		accrual of discount less \$	
(b) Includes \$	0	accrual of discount less \$0 amortization of premium and less \$0 paid for accrued dividends on purchases.	
(c) Includes \$	0	accrual of discount less \$0 amortization of premium and less \$0 paid for accrued interest on purchases.	
(d) Includes \$	0	for company's occupancy of its own buildings; and excludes \$0 interest on encumbrances.	
(e) Includes \$		accrual of discount less \$0 amortization of premium and less \$	
(f) Includes \$	0	accrual of discount less \$0 amortization of premium.	
	and Separate Acco	investment expenses and \$	
(h) Includes \$	0	interest on surplus notes and \$0 interest on capital notes.	
(i) Includes \$	0	depreciation on real estate and \$	

EXHIBIT OF CAPITAL GAINS (LOSSES)

		· · · · · · · · · · · · · · · · · · ·				
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)		Capital Gain (Loss)
1.	U.S. Government bonds		(162,629)	(134,667)	0	
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	143.001	0	.143.001	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	.0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments		0	15	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	(1)	0	(1)	0	0
10.	Total capital gains (losses)	170,977	(162,629)	8.348	0	0
	DETAILS OF WRITE-INS		())	, -		
0901.	Miscellaneous	(1)	0	(1)	0	0
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
0000.	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	(1)	0	(1)	0	0

ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Aetna Health of Iowa Inc. EXHIBIT OF NON-ADMITTED ASSETS

		EXHIBIT OF NON-ADMITTED ASSETS								
		1	2	3 Change in Total						
		Current Year Total	Prior Year Total	Nonadmitted Assets						
		Nonadmitted Assets	Nonadmitted Assets	, , , , , , , , , , , , , , , , , , , ,						
	Bonds (Schedule D)	0	0	0						
2.	Stocks (Schedule D):	0	0	0						
	2.1 Preferred stocks			0						
	2.2 Common stocks	0	0	0						
3.	Mortgage loans on real estate (Schedule B):									
	3.1 First liens		0	0						
	3.2 Other than first liens	0	0	0						
4.	Real estate (Schedule A):									
	4.1 Properties occupied by the company			0						
	4.2 Properties held for the production of income			0						
	4.3 Properties held for sale	0	0	0						
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)									
6.	Contract loans									
7.	Derivatives (Schedule DB)									
8.	Other invested assets (Schedule BA)	0	0	0						
9.	Receivables for securities	0	0	0						
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0						
11.	Aggregate write-ins for invested assets	0	0	0						
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0						
13.	Title plants (for Title insurers only)	0	0	0						
14.	Investment income due and accrued			0						
15.	Premiums and considerations:									
	15.1 Uncollected premiums and agents' balances in the course of collection									
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due									
	15.3 Accrued retrospective premiums and contracts subject to redetermination			0						
16.	Reinsurance:									
	16.1 Amounts recoverable from reinsurers	0	0	0						
	16.2 Funds held by or deposited with reinsured companies									
	16.3 Other amounts receivable under reinsurance contracts									
17	Amounts receivable relating to uninsured plans									
	Current federal and foreign income tax recoverable and interest thereon		0							
	Net deferred tax asset									
	Guaranty funds receivable or on deposit			-						
19.										
20.	Electronic data processing equipment and software			0						
21.	Furniture and equipment, including health care delivery assets			-						
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0						
23.	Receivable from parent, subsidiaries and affiliates									
24.	Health care and other amounts receivable			-						
25.	Aggregate write-ins for other than invested assets	0	0	0						
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	13, 113	43,314							
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0						
28.	Total (Lines 26 and 27)	13,113	43,314	30,201						
	DETAILS OF WRITE-INS									
1101.										
1102.										
1103.										
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0						
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0						
2501.		0	0	0						
2502.										
2503										
2503. 2598.	Summary of remaining write-ins for Line 25 from overflow page	٥	0	0						

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			1	otal Members at End o	f		6
		1	2	3	4	5	Current Year
-	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
1.	Health Maintenance Organizations		46				
2.	Provider Service Organizations	0	0	0	0	0	0
3.	Preferred Provider Organizations	0	0	0	0	0	0
4.	Point of Service		2,212	2,411			
5.	Indemnity Only	0	0	0	0	0	0
6.	Aggregate write-ins for other lines of business	0	0	0	0	0	0
7.	Total	1,874	2,258	2,457	2,755	2,820	30,130
	DETAILS OF WRITE-INS						
0601.		0	0	0	0	0	0
0602.		0	0	0	0	0	0
0603.		0	0	0	0	0	0
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying statutory financial statements of Aetna Health of Iowa Inc. (the "Company"), indirectly a wholly-owned subsidiary of CVS Health Corporation ("CVS Health"), have been prepared in conformity with accounting practices prescribed or permitted by the Iowa Insurance Division, Department of Commerce of the State of Iowa ("Iowa Insurance Division") ("Iowa Accounting Practices"). The Iowa Insurance Division recognizes statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners' ("NAIC") *Accounting Practices and Procedures Manual* ("NAIC SAP").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Iowa for the years ending December 31, 2021 and 2020 is as follows:

	SSAP #	Page	Line #		2021		2020
Iealth of Iowa Inc state basis (Page 4, Line 32, ns 2 & 3)	XXX	XXX	XXX	\$	3,549,301	\$	8,347,180
rescribed Practices that are an increase/(decrease) AIC SAP:							
ermitted Practices that are an increase/(decrease) NAIC SAP:					_		_
SAP (1-2-3=4)	XXX	XXX	XXX	\$	3,549,301	\$	8,347,180
Iealth of Iowa Inc state basis (Page 3, Line 33, ns 3 & 4)	XXX	XXX	XXX	\$	20,340,062	\$	46,809,793
rescribed Practices that are an increase/(decrease) AIC SAP:							
					—		—
ermitted Practices that are an increase/(decrease) AIC SAP:					_		_
SAP (5-6-7=8)	XXX	XXX	XXX	\$	20,340,062	\$	46,809,793
	 ns 2 & 3) rescribed Practices that are an increase/(decrease) AIC SAP: ermitted Practices that are an increase/(decrease) SAP (1-2-3=4) Health of Iowa Inc state basis (Page 3, Line 33, ns 3 & 4) rescribed Practices that are an increase/(decrease) AIC SAP: ermitted Practices that are an increase/(decrease) AIC SAP: 	ns 2 & 3) XXX rescribed Practices that are an increase/(decrease) XXX ermitted Practices that are an increase/(decrease) XXX SAP (1-2-3=4) XXX Iealth of Iowa Inc state basis (Page 3, Line 33, ns 3 & 4) XXX rescribed Practices that are an increase/(decrease) XXX ermitted Practices that are an increase/(decrease) XXX	ns 2 & 3) XXX XXX XXX rescribed Practices that are an increase/(decrease) AIC SAP: XXX XXX ermitted Practices that are an increase/(decrease) XXX XXX XXX SAP (1-2-3=4) XXX XXX XXX Iealth of Iowa Inc state basis (Page 3, Line 33, ns 3 & 4) XXX XXX XXX rescribed Practices that are an increase/(decrease) XXX XXX XXX rescribed Practices that are an increase/(decrease) XXX XXX XXX ermitted Practices that are an increase/(decrease) AIC SAP: AIC SAP: AIC SAP:	ns 2 & 3) XXX XXX	ns 2 & 3) XXX XXX	ns 2 & 3) XXX XXX XXX XXX XXX XXX \$ 3,549,301 rescribed Practices that are an increase/(decrease)	ns 2 & 3) XXX XXX

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with Iowa Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting Policies

The Company applies the following significant accounting policies:

(1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

(2) Bonds

Bonds are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets

for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2021 or 2020. Bonds include all investments whose maturity is greater than one year when purchased. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus.

Bonds are recorded as purchases or sales on the trade date.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities ("LB&SS") discussed in Note 1 C. (6) below, an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-thantemporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

The Company had no Securities Valuation Office-identified investments that are being reported at a different measurement method from the prior year annual statement.

(3) Common Stocks

The Company did not own any common stock at December 31, 2021 or 2020.

(4) Preferred Stocks

The Company did not own any preferred stock at December 31, 2021 or 2020.

(5) Mortgage Loans

The Company did not have any mortgage loans at December 31, 2021 or 2020.

(6) Loan-Backed and Structured Securities

LB&SS are carried at amortized cost adjusted for unamortized premiums and discounts and are accounted for using the retrospective adjustment method. Premiums and discounts on loan-backed and structured securities are amortized using the scientific method over the estimated remaining term of the securities, adjusted for anticipated prepayments.

For LB&SS, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

(7) Investments in Subsidiaries, Controlled or Affiliated Companies

The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2021 or 2020.

(8) <u>Investments in Joint Ventures, Partnerships and Limited Liability Companies</u>

The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2021 or 2020.

(9) <u>Derivatives</u>

The Company did not have any derivatives at December 31, 2021 or 2020.

(10) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Anticipated investment income is not considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts.

Unearned premium reserves ("UEP") are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The Company had no UEP at December 31, 2021. The UEP balances of \$411 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2020.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios ("MLR") were not met in the prior year. The Company's results for full year 2021 and 2020 include estimates of \$5,558,787 and \$5,053,442, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities and Capital and Surplus.

The Company contracts with the Office of Personnel Management ("OPM") to provide managed health care services under the Federal Employees Health Benefits ("FEHB") program in its service areas. OPM regulations require that FEHB plans meet a FEHB program-specific MLR by plan code and market.

The Company reported Federal Contingency Reserve of \$219,144 and \$444,842 in aggregate health policy reserves at December 31, 2021 and 2020, respectively.

For Medicare plans, the Company's annual contract with Centers for Medicare & Medicaid Services ("CMS") provides a risk-sharing arrangement to limit exposure to unexpected expenses. The risk-sharing arrangement provides a risk corridor whereby the amount the Company received in premiums from members and CMS based on its annual bid is compared to actual drug costs incurred during the contract year. Based on the risk corridor provision and Part D activity-to-date, no estimated risk-sharing payables were recorded in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2021 and 2020.

The Company reported liabilities associated with contracts subject to redetermination as aggregate health policy reserves in accordance with SSAP No. 54 - Revised - *Individual and Group and Accident Health Contracts* ("SSAP No. 54"). Liabilities associated with estimated adjustments to premium payments to the Company's Medicare plans based on the health status of its Medicare members are included as part of the Company's contracts subject to redetermination. Amounts related to these liabilities are \$36,689 and are included in aggregate health policy reserves at December 31, 2021. The Company had no such liabilities at December 31, 2020.

(11) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

(12) Capitalization Policy

The Company has not modified its capitalization policy from the prior period.

(13) Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within one month of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled monthly with an affiliated entity, including adjustments to previously billed periods. The pharmaceutical rebate receivables are more fully discussed in Note 28.

(14) Premiums and Amounts Due and Unpaid

Premium revenue for prepaid health or dental care products is recognized as income in the month in which enrollees are entitled to health or dental care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums and are included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus.

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

Through the Company's Medicare Advantage Part D annual contract with CMS, the Company receives monthly premium payments from CMS and members, as determined by the Company's annual bid process. The Company recognizes the revenue related to the CMS contract ratably over the term of its annual contract.

The CMS payment is subject to risk sharing provisions through the CMS risk corridor provision, which is accounted for as a retrospectively rated contract in accordance with SSAP No. 66 - *Retrospectively Rated Contracts*. Receivables related to the CMS risk corridor provision are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

The Company's CMS payment is also subject to the CMS risk adjustment process for each member, which is accounted for as a contract subject to redetermination in accordance with SSAP No. 54. Receivables related to the CMS risk adjustment process are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

(15) Aggregate Health Claim Reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

(16) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2021 and 2020, the Company did not have any nonadmitted investment income due and accrued.

(17) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(18) Fees Paid to the Federal Government by Health Insurers

SSAP No. 106 - *Affordable Care Act Section 9010 Assessment* ("SSAP No. 106") required (1) that the annual fee be recognized in full on January 1 of the fee year (the calendar year in which the assessment must be paid to the federal government), in the operating expense category of general administrative expenses, excluding federal income taxes and (2) that in each data year preceding a fee year a reporting entity pro-ratably accrue by reclassifying from unassigned surplus to special surplus funds an amount equal to its estimated subsequent fee year assessment. This reclassification has no impact on total capital and surplus and is reversed in full on January 1 of the fee year. On January 1, 2020, the Company was subject to the annual fee ("ACA assessment"). This annual fee was allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that was written during the preceding calendar year. A health risk for each

calendar year beginning on or after January 1 of the year the fee is due. In September 2020, the Company paid \$113,900 to the federal government for its portion of the annual fee. In December 2019, the annual fee was repealed beginning in 2021. As a result of this repeal, there was no annual fee payable in 2021 and thereafter, and therefore no estimated subsequent fee year assessment was required to be reclassified from unassigned funds to special surplus funds at December 31, 2021 and December 31, 2020.

(19) <u>The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's</u> (collectively, the "ACA") Risk Adjustment

The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company's qualified plan members relative to the average risk of members of other qualified plans in comparable markets, the Company estimates its ultimate risk adjustment receivable or payable for the current calendar year and reflects the impact as an adjustment to its premium revenue in accordance with SSAP No. 107 - Risk-Sharing Provisions of the Affordable Care Act ("SSAP No. 107").ACA Risk Adjustment payables are included in aggregate health policy reserves on the Statutory Statements of Liabilities, Capital and Surplus. ACA Risk Adjustment receivables are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

(20) <u>Reinsurance</u>

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums and claims ceded and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Notes 23.

(21) Federal and State Income and Premium Taxes

Aetna Inc. ("Aetna") and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its ultimate parent company, CVS Health, pursuant to the terms of a tax sharing agreement. In accordance with the agreement, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent expected to be realized in the consolidated return. Pursuant to the agreement, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101 - *Income Taxes*. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

- a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Code ("IRC") tax loss carryback provisions.
- b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in various states. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses.For the years ended December 31, 2021 and 2020, the Company incurred state income tax expenses of \$74,256 and \$289,484, respectively.

The Company had \$4,849 of state income tax receivables at December 31, 2021. These balances were included as aggregate write-ins for other than invested assets in the Statutory Statements of Assets.

The Company had \$136,889 of state income tax payables at December 31, 2020. These balances were included in general expenses due or accrued in the Statutory Statements of Liabilities, Capital and Surplus.

The Company is subject to premium taxes in the State of Iowa. These tax expenses were recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. The expenses for these taxes were \$18,758 and \$48,910 for the years ended December 31, 2021 and 2020, respectively.

The Company had premium taxes payable of \$1,240 at December 31, 2021, respectively. These balances were included in general expenses due or accrued in the Statutory Statements of Liabilities, Capital and Surplus.

The Company had an overpayment of premium taxes of \$56,106 at December 31, 2020. These balances were included as aggregate write-in's for other than invested assets in the Statutory Statements of Assets.

D. Going Concern

As of February 25, 2022, management evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern and management has determined that it is not probable that the Company will be unable to meet its obligations as they become due within one year after the financial statements are available to be issued. Management will continuously evaluate the Company's ability to continue as a going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2021 and 2020.

3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2021 and 2020.

4. Discontinued Operations

The Company did not have any operations receiving discontinued operations accounting treatment during the years ending December 31, 2021 and 2020.

5. Investments

- A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2021 or 2020.
- B. The Company did not have any debt restructuring in the years ending December 31, 2021 or 2020.
- C. The Company did not have any reverse mortgages at December 31, 2021 or 2020.
- D. Loan-Backed Securities
 - (1) Prepayment assumptions for single class and multi-class mortgage-backed/loan-backed securities were obtained from industry market sources.
 - (2) The Company did not recognize any other-than-temporary impairments ("OTTI") on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R *Loan-Backed and Structured Securities* ("SSAP No. 43R") at December 31, 2021.
 - (3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis at December 31, 2021.
 - (4) The Company's unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2021 is as follows:

a.	The aggregate amount of unrealized losses:	
	1. Less than 12 Months	\$ (6,081)
	2. 12 Months or Longer	(8,708)
b.	The aggregate related fair value of securities with unrealized losses:	
	1. Less than 12 Months	\$ 245,572
	2. 12 Months or Longer	500,128

- (5) The Company has reviewed the loan-backed and structured securities in accordance with SSAP No. 43R in the table above and has concluded that these are performing assets generating investment income to support the needs of the business. Furthermore, the Company has no intention to sell the securities at December 31, 2021 before their cost can be recovered and does have the intent and ability to retain the securities for the time sufficient to recover the amortized cost basis; therefore, no OTTI write-down to fair value was determined to have occurred on these securities.
- E. The Company had no dollar repurchase agreements and/or securities lending transactions at December 31, 2021.
- F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2021.
- G. The Company did not have any reverse repurchase agreements transactions accounted for as secured borrowing at December 31, 2021.
- H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2021.
- I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2021.
- J. The Company did not have any real estate at December 31, 2021.
- K. The Company did not have any low-income housing tax credits at December 31, 2021 or 2020.
- L. Restricted Assets
 - (1) The Company did not have any restricted assets (including pledged) at December 31, 2021 or 2020.
 - (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2021 or 2020.
 - (3) The Company did not have any other restricted assets at December 31, 2021 or 2020.
 - (4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2021.
- M. The Company did not have any working capital finance investments at December 31, 2021.
- N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2021.
- O. The Company did not have any 5GI securities at December 31, 2021 or 2020.
- P. The Company did not have any short sales within the reporting period.
- Q. The Company did not have any prepayment penalty and acceleration fees at December 31, 2021.
- R. The Company did not participate in any qualified cash pools at December 31, 2021.
- 6. Joint Ventures, Partnerships, and Limited Liability Companies
 - A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2021 or 2020.
 - B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2021 or 2020.
- 7. Investment Income
 - A. Due and accrued income was excluded from surplus on the following bases:

Bonds - where collection of interest is uncertain.

- B. There was no amount excluded at December 31, 2021 or 2020.
- 8. Derivative Instruments

The Company did not have any derivative instruments at December 31, 2021 or 2020.

9. <u>Income Taxes</u>

Α.

(1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

			12/31/2021			12/31/2020				
		(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a)	Gross Deferred Tax Assets	\$ 60,023	\$ 138,956	\$ 198,979	\$ 107,206	\$ 134,141	\$ 241,347	\$ (47,183)	\$ 4,815	\$ (42,368)
(b)	Statutory Valuation Allowance Adjustment	_	_	_	_	_	_	_	_	_
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	60,023	138,956	198,979	107,206	134,141	241,347	(47,183)	4,815	(42,368)
(d)	Deferred Tax Assets Nonadmitted	_	11,257	11,257	10,848	30,268	41,116	(10,848)	(19,011)	(29,859)
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	60,023	127,699	187,722	96,358	103,873	200,231	(36,335)	23,826	(12,509)
(f)	Deferred Tax Liabilities	29,382	103,557	132,939	36,549	89,525	126,074	(7,167)	14,032	6,865
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 30,641	\$ 24,142	\$ 54,783	\$ 59,809	\$ 14,348	\$ 74,157	\$ (29,168)	\$ 9,794	\$ (19,374)

(2) The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

			12/31/2021			12/31/2020				
		(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
	ission Calculation Components P No. 101	orunniy	Capitai	Total	Orunnary	Capitar	Total	Ordiniary	Capitai	1000
(a)	Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks.	\$ 59,546	\$ 24,143	\$ 83,689	\$ 59,679	\$ 14,348	\$ 74,027	\$ (133)	\$ 9,795	\$ 9,662
(b)	Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	133		133	130		130	3		3
	1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date.	133	_	133	130	_	130	3	_	3
	2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XX	XX	3,042,792	XX	XX	7,010,345	XX	XX	(3,967,553)
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	344	103,556	103,900	36,549	89,525	126,074	(36,205)	14,031	(22,174)
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 60,023	\$ 127,699	\$ 187,722	\$ 96,358	\$ 103,873	\$ 200,231	\$ (36,335)	\$ 23,826	\$ (12,509)

(3)

		 2021	2020
(a)	Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	1,047 %	4,063 %
(b)	Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	\$ 20,285,279	\$ 46,735,636

(4) The impact of tax planning strategies is as follows:

	12/31	/202	21	12/31	1/2020			Cha		;
	(1)		(2)	(3)		(4)		(5) (Col. 1 - 3)		(6) (Col. 2 - 4)
	Ordinary		Capital	Ordinary		Capital		Ordinary		Capital
Impact of Tax Planning Strategies:										
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.										
1. Adjusted Gross DTAs amount from Note 9A1(c)	\$ 60,023	\$	138,956	\$ 107,206	\$	134,141	\$	(47,183)	\$	4,815
Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	— %		— %	— %		%	,	— %		— %
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	60,023		127,699	96,358		103,873		(36,335)		23,826
 Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies 	— %		— %	— %		— %	,	<u> </u>		— %

(b) Do the Company's tax-planning strategies include the use of reinsurance?

- B. There are no DTLs that were not recognized at December 31, 2021 or 2020.
- C. Current income taxes incurred consist of the following major components:

		(1)	(2)	(3)
1 0	urrent Income Tax	12/31/2021	12/31/2020	(Col. 1 - 2)
				Change
(a		\$ 733,675	\$ 1,987,613	\$ (1,253,938)
(b			1.007.(12	(1.252.020)
(c		733,675	1,987,613	(1,253,938)
(d	· · · ·	(344)	287	(631)
(e		_	_	_
(f			1.007.000	(1.054.5(0))
(g	g) Federal and foreign income taxes incurred	733,331	1,987,900	(1,254,569)
2. D (a	eferred Tax Assets: a) Ordinary:			
(a	(1) Discounting of unpaid losses	13,267	13,060	207
		13,207	· · · · · · · · · · · · · · · · · · ·	
	(2) Unearned premium reserve	1	113	(112)
	(3) Policyholder reserves(4) Investmente	_	_	_
	(4) Investments	_	_	_
	(5) Deferred acquisition costs	_	_	_
	(6) Policyholder dividends accrual	_	_	—
	(7) Fixed Assets	_	—	_
	(8) Compensation and benefits accrual	_	—	—
	(9) Pension accrual	_	—	_
	(10) Receivables - nonadmitted	390	462	(72)
	(11) Net operating loss carry-forward	_	_	_
	(12) Tax credit carry-forward	—	—	—
	(13) Other (including items <5% of total ordinary tax assets)	46,365	93,571	(47,206)
	(99) Subtotal	60,023	107,206	(47,183)
(b	b) Statutory valuation allowance adjustment	_	_	—
(c	e) Nonadmitted		10,848	(10,848)
(d (e		60,023	96,358	(36,335)
	(1) Investments	138,956	134,141	4,815
	(2) Net capital loss carry-forward	_	_	_
	(3) Real estate	_	_	_
	(4) Other (including items <5% of total ordinary tax assets)	_	_	_
	(99) Subtotal	138,956	134,141	4,815
(f	f) Statutory valuation allowance adjustment	_	_	_
(g		11,257	30,268	(19,011)
(h		127,699	103,873	23,826
(i		187,722	200,231	(12,509)
8. D	eferred Tax Liabilities:			
(a	a) Ordinary:			
	(1) Investments	7,883	7,884	(1)
	(2) Fixed assets	_	_	_
	(3) Deferred and uncollected premium	_	_	_
	(4) Policyholder reserves	_	_	_
	(5) Other (including items <5% of total ordinary tax liabilities)	21,499	28,665	(7,166)
	(99) Subtotal	29,382	36,549	(7,167)
(b	b) Capital:			
	(1) Investments	103,557	89,525	14,032
	(2) Real estate			–
	(3) Other (including items <5% of total capital tax liabilities)			–
	(99) Subtotal	103,557	89,525	14,032
(c	c) Deferred tax liabilities (3a99 + 3b99)	132,939	126,074	6,865
4. N	let deferred tax assets/liabilities (2i - 3c)	\$ 54,783		

The change in net deferred income taxes is comprised of the following:

	1	12/31/2021	12/31/2020	Change
Total Deferred Tax Assets	\$	198,979 \$	241,347 \$	(42,368)
Total Deferred Tax Liabilities		(132,939)	(126,074)	(6,865)
Net Deferred Tax Assets/(Liabilities)		66,040	115,273	(49,233)
Tax Effect of Unrealized Gains/(Losses)				
Change in Net Deferred Income Tax			\$	(49,233)

There was no valuation allowance adjustment to gross DTAs as of December 31, 2021 or 2020. The Company bases its estimates of the future realization of DTAs primarily on historic taxable income and existing DTLs.

D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

	 12/31/2021	Effective Tax Rate		12/31/2020	Effective Tax Rate
Provision computed at statutory rate	\$ 899,353	21.0 %	\$	2,170,659	21.0 %
Health insurer fee		0.0 %		23,919	0.2 %
Transfer pricing adjustment	(65,853)	(1.5)%		(52,716)	(0.5)%
Tax-exempt interest	(51,398)	(1.2)%		(82,036)	(0.8)%
Change in nonadmitted assets	72	0.0 %		30,591	0.3 %
Prior year true-up	390	0.0 %		5,514	0.1 %
Change in valuation allowance adjustment	_	0.0 %		—	0.0 %
Other	 	0.0 %		91	0.0 %
Total	\$ 782,564	18.3 %	\$	2,096,022	20.3 %
Federal and foreign income taxes incurred	\$ 733,331	17.2 %	\$	1,987,900	19.3 %
Change in net deferred income taxes	 49,233	1.1 %		108,122	1.0 %
Total statutory income taxes	\$ 782,564	18.3 %	\$	2,096,022	20.3 %

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices (i.e., prices at which unrelated entities would be willing to transact), which results in a permanent deduction for tax reporting purposes.

E.

- (1) At December 31, 2021 and 2020, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- (2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

Year	 Ordinary	Capital	Total
2021	\$ 724,174	\$ 6,567	\$ 730,741
2020	1,992,200	_	1,992,200
2019	 —	34,234	34,234
Total	\$ 2,716,374	\$ 40,801	\$ 2,757,175

(3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2021 and 2020.

F.

(1) At December 31, 2021, the Company's Federal Income Tax Return was consolidated with the following entities:

CORAM HEALTHCARE CORPORATION OF NORTHERN CALIFORNIA
CORAM HEALTHCARE CORPORATION OF SOUTHERN CALIFORNIA
CORAM HEALTHCARE CORPORATION OF SOUTHERN FLORIDA
CORAM HEALTHCARE CORPORATION OF UTAH
Coventry Consumer Advantage, Inc.
Coventry Health and Life Insurance Company
Coventry Health Care National Accounts, Inc.
Coventry Health Care National Network, Inc.
Coventry Health Care of Illinois, Inc.

Aetna Better Health Inc. (NY) Aetna Better Health Inc. (OH) Aetna Better Health of California, Inc. Aetna Better Health of Florida, Inc. (F/K/A Coventry Health Care of Florida, Inc.) Aetna Better Health of Illinois, Inc. (F/K/A IlliniCare Health Plan, Inc.) Aetna Better Health of Indiana Inc Aetna Better Health of Kansas Inc. Aetna Better Health of Kentucky Insurance Co. Aetna Better Health of Michigan, Inc Aetna Better Health of Missouri LLC Aetna Better Health of Nevada Inc. Aetna Better Health of North Carolina, Inc. Aetna Better Health of Oklahoma Inc. Aetna Better Health of Tennessee Inc. (F/K/A Aetna Better Health Inc. (TN)) Aetna Better Health of Texas, Inc. Aetna Better Health of Washington, Inc. Aetna Better Health Premier Plan MMAI Inc. (f/n/a Aetna Better Health Inc. (IL)) Aetna Better Health, Inc. (Connecticut) Aetna Better Health, Inc. (LA) Aetna Better Health, Inc. (PA) Aetna Corporate Services LLC Aetna Dental Inc. (New Jersey) Aetna Dental Inc. (Texas) Aetna Dental of California, Inc. Aetna Florida, Inc. AETNA HEALTH AND LIFE INSURANCE COMPANY Aetna Health Inc. (Connecticut) Aetna Health Inc. (Florida) Aetna Health Inc. (Georgia) Aetna Health Inc. (LA) Aetna Health Inc. (Maine) Aetna Health Inc. (New Jersev) Aetna Health Inc. (NY) Aetna Health Inc. (Pennsylvania) Aetna Health Inc. (Texas) Aetna Health Insurance Co Aetna Health Insurance Company of New York Aetna Health of California Inc. Aetna Health of Iowa, Inc Aetna Health of Michigan Inc. (F/K/A Aetna Health Inc. (Michigan)) Aetna Health of Ohio, Inc. (F/K/A Aetna Better Health of Iowa, Inc.) Aetna Health of Utah, Inc. Aetna HealthAssurance Pennsylvania, Inc. Aetna Inc. Aetna Integrated Informatics, Inc. Aetna Ireland Inc. Aetna Risk Assurance Company of Connecticut Aetna Student Health Agency, Inc. ALABAMA CVS PHARMACY, L.L.C. American Health Holding, Inc. APRIA FINANCE HOLDINGS, INC. AUSHC Holdings, Inc. (CT) BRUIN ACQUISITION CO., INC. bswift. LLC Carefree Insurance Services, Inc. CAREMARK ULYSSES HOLDING CORP. Claims Administration Corporation Cofinity, Inc. CONNECTICUT CVS PHARMACY, L.L.C. CORAM ALTERNATE SITE SERVICES. INC. CORAM HEALTHCARE CORPORATION OF ALABAMA CORAM HEALTHCARE CORPORATION OF FLORIDA CORAM HEALTHCARE CORPORATION OF GREATER D.C. CORAM HEALTHCARE CORPORATION OF GREATER NEW YORK CORAM HEALTHCARE CORPORATION OF INDIANA

CORAM HEALTHCARE CORPORATION OF MASSACHUSETTS

Coventry Health Care of Kansas, Inc. Coventry Health Care of Missouri, Inc. Coventry Health Care of Nebraska, Inc. Coventry Health Care of Virginia, Inc. Coventry Health Care of West Virginia, Inc. Coventry Health Plan of Florida, Inc. Coventry HealthCare Management Corporation Coventry Prescription Management Services, Inc. Coventry Transplant Network, Inc. CVS AOC Corporation CVS ARCLIGHT, INC. CVS CAREMARK INDEMNITY LTD. CVS FOREIGN, INC. CVS INTERNATIONAL, L.L.C. CVS PHARMACY, INC. CVS PR CENTER INC CVS RX SERVICES, INC. CVS WWRE, INC. DELAWARE CVS PHARMACY, L.L.C. Delaware Physicians Care, Inc. E.T.B., INC. Echo Merger Sub, Inc ECKERD CORPORATION OF FLORIDA, INC. First Health Group Corp. First Health Life and Health Insurance Company Florida Health Plan Administrators, LLC Group Dental Service of Maryland, Inc. Group Dental Service, Inc. Health and Human Resource Center, Inc. Health Data & Management Solutions, Inc. Health Re, Inc. HealthAssurance Pennsylvania. Inc. HOLIDAY CVS, L.L.C IOWA CVS PHARMACY, L.L.C. KENTUCKY CVS PHARMACY, L.L.C. Managed Care Coordinators, Inc. MARYLAND CVS PHARMACY, L.L.C. MASSACHUSETTS CVS PHARMACY, INC. MELVILLE REALTY CO., INC. Mental Health Associates. Inc. Mental Health Network of New York IPA, Inc. Meritain Health. Inc. MHNet of Florida, Inc. MINUTECLINIC DIAGNOSTIC OF ILLINOIS. L.L.C. MinuteClinic Physician Practice of Texas MinuteClinic Telehealth Services of Texas Association Niagara Re. Inc. NORTH CAROLINA CVS PHARMACY, L.L.C. OKLAHOMA CVS PHARMACY, L.L.C. PayFlex Holdings, Inc. PavFlex Systems USA. Inc Performax, Inc. Precision Benefit Services, Inc. PrimeNet. Inc. Prodigy Health Group, Inc. Professional Risk Management, Inc. Resources for Living, LLC RETRAC, INC. RICHMOND HEIGHTS ACOUISITION CORP. Schaller Anderson Medical Administrators Inc SILVERSCRIPT INSURANCE COMPANY SKY ACOUISITION LLC T2 MEDICAL. INC. TENNESSEE CVS PHARMACY, L.L.C.

The Vasquez Group, Inc. U.S. Health Care Properties, Inc.

CORAM HEALTHCARE CORPORATION OF MISSISSIPPI CORAM HEALTHCARE CORPORATION OF NEVADA CORAM HEALTHCARE CORPORATION OF NORTH TEXAS UAC HOLDING, INC. VIRGINIA CVS PHARMACY, L.L.C. Work & Family Benefits, Inc.

- (2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.
- G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- H. The Company was not subject to the Repatriation Transition Tax at December 31, 2021 and 2020.
- I. The Company did not recognize any gross Alternative Minimum Tax credit at December 31, 2021 and 2020.
- 10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties
 - A. and B.:

Transactions occurring between the Company and its parent, subsidiaries and affiliates excluding reinsurance transactions and non-insurance transactions involving less than $\frac{1}{2}$ of 1% of the Company's total admitted assets and cost allocation transactions follow:

December 31, 2021

				 Assets receive	ed by insurer	A	Assets transfe	rred by insurer
Date of transaction	Explanation of transaction	Name of reporting entity	Name of affiliate	Statement value	Statement description		Statement value	Statement description
June 1, 2021	Extraordinary Dividend	Aetna Health of Iowa Inc.	Aetna Health Holdings, LLC	\$ _		\$	30,000,000	Cash

December 31, 2020

				Asse	ts receive	ed by insurer	A	ssets transfer	red by insurer	_
Date of transaction	Explanation of transaction	Name of reporting entity	Name of affiliate	State		Statement description	ŝ	Statement value	Statement description	_
December 7, 2020	Ordinary Dividend	Aetna Health Of Iowa Inc.	Aetna Health Holdings, LLC	\$	_		\$	4,200,000	Cash	

C. The Company did not have any transactions with related parties who are not reported on Schedule Y at December 31, 2021.

D. At December 31, 2021 and 2020, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreements if applicable.

		December 31,			
	2021 2020				
Amounts due to affiliates					
Aetna Health Management, LLC	\$	1,127,413 \$	1,054,971		
Total due to affiliates	\$	1,127,413 \$	1,054,971		

At December 31, 2021 and 2020, the Company had no amounts due from affiliates.

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

E. As of and for the years ended December 31, 2021 and 2020, the Company had the following significant transactions with affiliates:

The Company and Aetna Health Management, LLC ("AHM") are parties to an administrative services agreement, under which AHM provides certain administrative services, including accounting and processing of premiums and claims. Under this agreement, the Company remits a percentage of its earned commercial and Medicare premium revenue, as applicable, to AHM as a fee, subject to an annual true up mechanism as defined in the agreement. Under the agreement, this true-up is due to be settled with the affiliate by April 15th of the following contract year (which is January 1 to December 31 annually). The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter. The agreement was amended effective January 1, 2020 and approved by the State of Iowa on September 13, 2019. The amendment allows other affiliates to provide services in accordance to a schedule of services and pricing. For these services, the Company was charged \$4,526,735 and \$3,316,498 in 2021 and 2020, respectively.

The Company is a party to an agreement which enables the Company to receive manufacturers' pharmacy rebates from AHM. The Company earned pharmaceutical rebates of \$6,235,871 and \$3,517,544, which were recorded as a reduction of medical costs, in 2021 and 2020, respectively.

These agreements also provide for interest on all intercompany balances. Interest earned on amounts due from affiliates was \$624 in 2021 and \$7,351 in 2020. Interest incurred on amounts due to affiliates was \$1,829 in 2021 and \$2,937 in 2020.

As explained in Note 1, Aetna and its wholly-owned subsidiaries, including the Company, participate in a tax sharing agreement with CVS Health. All federal income tax receivables/payables are due from/due to CVS Health.

- F. The Company does not have any guarantees or undertakings, written or otherwise, at December 31, 2021.
- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.
- H. At December 31, 2021, the Company did not own shares of an upstream intermediate entity or CVS Health, either directly or indirectly.
- I. At December 31, 2021, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.
- J. At December 31, 2021, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2021, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2021, the Company did not hold any investments in a downstream noninsurance holding company.
- M. At December 31, 2021, the Company did not have any SCA investments.
- N. At December 31, 2021, the Company did not have any investments in an insurance SCA.
- O. The Company did not have any SCA or SSAP No. 48 entity investments where the Company's share of losses in the SCA exceeds its investment in the SCA.
- 11. <u>Debt</u>
 - A. The Company did not have any items related to debt, including capital notes at December 31, 2021.
 - B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2021.
- 12. <u>Retirement Plans</u>, <u>Deferred Compensation</u>, <u>Postemployment Benefits and Compensated Absences and Other Postretirement</u> Benefit Plans

A.- I. The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2021 or 2020.

- 13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations
 - A. The Company had 1,000,000 shares of authorized common capital stock, with a par value of \$5 per share and 253,567 shares issued and outstanding as of December 31, 2021 and 2020.
 - B. The Company had no shares of preferred stock issued and outstanding at December 31, 2021 and 2020.
 - C. Dividend Restrictions

Dividends on the Company's common capital stock are paid as declared by its Board of Directors, from earned surplus of the Company, not including surplus arising from the sale of stock. Generally, dividends may be paid on the Company's common capital stock without obtaining regulatory approval at an amount up to the greater of: a) the prior year net gain from operations, or b) ten percent of the prior year ending capital and surplus. In addition the minimum Risk Based Capital requirements of the NAIC and, if applicable, the Iowa Insurance Division must be maintained.

D. The Company paid \$30,000,000 as an extraordinary dividend to its parent on June 1, 2021. The Iowa Insurance Division approved this dividend on May 17, 2021.

The Company paid \$4,200,000 as an ordinary dividend to its parent on December 7, 2020.

- E. Within the limitations of (C) above, there are no other restrictions placed on the portion of the Company profits that may be paid as ordinary dividends to stockholders.
- F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. The Company had no advances to surplus not repaid.
- H. The Company did not hold any stock for any special purposes at December 31, 2021 or 2020.
- I. There were no changes in the balances of special surplus funds from the prior year.
- J. At December 31, 2021, there were no unassigned funds that were represented or reduced by unrealized gains and losses.

K. The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2021 or 2020.

L. The Company did not participate in any quasi-reorganizations during the statement year.

- M. The Company did not participate in any quasi-reorganizations in the past 10 years.
- 14. Liabilities, Contingencies and Assessments
 - A. The Company did not have any contingent commitments at December 31, 2021 or 2020.
 - B. Assessments

Guaranty Fund Assessments

(1) Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company's assessments generally are based on a formula relating to the Company's health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payers such as not-for-profit consumer-governed health plans established under the ACA.

The Company did not have any contingent assessments at December 31, 2021 or 2020.

- C. The Company did not have any gain contingencies at December 31, 2021 or 2020.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2021 or 2020.
- E. The Company did not have any joint and several liability arrangements at December 31, 2021 or 2020.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company maintains insurance coverage for certain litigation exposures in an amount it believes is reasonable.

15. Leases

The Company did not have any material lease obligations at December 31, 2021 or 2020.

16. <u>Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit</u> <u>Risk</u>

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2021 or 2020.

- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
 - A. Transfers of Receivables Reported as Sales

The Company did not have any transfers of receivables reported as sales for the years ending December 31, 2021 or 2020.

- B. Transfer and Servicing of Financial Assets
 - (1) The Company did not have any loaned securities at December 31, 2021 or 2020.
 - (2) and (3):

The Company did not have any servicing assets or liabilities at December 31, 2021 or 2020.

- (4) The Company did not have any securitized financial assets at December 31, 2021 or 2020.
- (5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2021 or 2020.
- (6) The Company did not have any transfers of receivables with recourse at December 31, 2021 or 2020.
- (7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2021 or 2020.

C. <u>Wash Sales</u>

- (1) In the course of the Company's asset management, securities are sold and reacquired within 30 days of the sale date to enhance the Company's yield on its investment portfolio.
- (2) The Company had no securities sold during the year for the year ended December 31, 2021 and reacquired within 30 days of the sale date.
- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
 - A. The Company did not serve as an Administrative Services Only ("ASO") plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2021.
 - B. The Company did not serve as an Administrative Services Contract plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2021.
 - C. Medicare or Similarly Structured Cost Based Reimbursement Contract:
 - (1) Revenue from the Company's Medicare (or similarly structured cost based reimbursement contract) contract for the year 2021 was \$42,829,873.
 - (2) As of December 31, 2021, the Company has recorded receivables from the following payors whose account balances are greater than 10% of the Company's amounts receivable from uninsured accident and health plans or \$10,000:

Centers for Medicare and Medicaid Services \$3,144,118

- (3) In connection with the Company's Medicare (or similarly structured cost based reimbursement contract) contract, the Company has recorded allowance and reserves for adjustment of recorded revenues as and if applicable.
- (4) CMS periodically perform audits of Medicare revenue and may seek return of premium payments made to the Company if risk adjustment factors are not properly supported by medical record data. The Company estimates and records reserves for CMS audits based on information available at the time the estimates are made. Although the Company believes it maintains appropriate reserves for its exposure to the CMS audits, actual results could differ materially from those estimates.
- 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2021 and 2020.

20. Fair Value Measurements

A.

- (1) The Company had no material assets and liabilities that are measured and reported at fair value in the financial statements as of December 31, 2021 and 2020.
- (2) There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2021 or 2020.
- (3) Transfers in and out of all levels are recognized at the end of the reporting period of which the transfer occurred.
- (4) The Company's fair value measurement valuation techniques are described in B. below.
- (5) The Company did not have any derivative instruments at December 31, 2021 or 2020.
- B. The fair values of the Company's financial instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:
 - Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets.
 - Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
 - Level 3 Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market

prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2021 and 2020 were as follows:

December 31, 2021

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, Short Term, and Cash Equivalents	\$ 22,304,839	\$ 21,248,403	\$ 2,495,736	\$ 19,809,103	s —	\$ —	\$

December 31, 2020

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, Short Term, and Cash Equivalents	\$ 48,446,930	\$ 46,688,472	\$ 2,608,421	\$ 45,838,509	s –	\$ _	\$ _

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

- D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.
- E. The Company has not elected to use the net asset value practical expedient to fair value to measure its investments.

21. Other Items

A. Unusual or Infrequent Items

Risk Corridor

The ACA established a temporary risk corridor program, which expired at the end of 2016, for qualified individual and small group health insurance plans. Under this program, health insurance companies were to make payments to, or receive payments from, the U.S. Department of Health and Human Services ("HHS") based on their ratio of allowable costs to target costs (as defined by the ACA).

CVS Health, together with its subsidiaries, filed a lawsuit in August 2019 to recover the approximately \$310 million it was owed under the ACA's risk corridor program, which had been stayed pending the Supreme Court decision. In April 2020, the U.S. Supreme Court ruled that health insurance companies may sue the federal government for amounts owed as calculated under the ACA's temporary risk corridor program.

In October 2020, the Company received the funds owed under the ACA's risk corridor program. The Company recorded the risk corridor payment of \$4,330,007 as an increase to premium revenue in the fourth quarter of 2020.

B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2021 and 2020.

C. Other Disclosures

Minimum Capital and Surplus

The Company is subject to certain regulations found in the Iowa Administrative Code, which require the Company to maintain capital and surplus of at least \$1 million. At both December 31, 2021 and 2020, the Company was in compliance with the minimum surplus and capital stock requirements of the State of Iowa in which it is licensed to do business.

The NAIC utilizes risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of a company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2021 and 2020, the Company had capital and surplus that exceeded the highest threshold specified by the RBC rules.

COVID-19

The Coronavirus Disease 2019 ("COVID-19") pandemic continues to evolve. The Company believes COVID-19's impact on the Company's businesses, operating results, cash flows and/or financial condition primarily will be driven by the

geographies impacted and the severity and duration of the pandemic; the pandemic's impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company's knowledge and control. As a result, the impact COVID-19 will have on the Company's businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company.

Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the "ACA"), made broad-based changes to the United States health care system. In June 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety and issued an opinion preserving the ACA and its consumer protections in its current form. Even though the ACA was deemed constitutional, there may nevertheless be continued efforts to invalidate, modify, repeal or replace portions of it. In addition to litigation, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance at the federal or state level. The Company expects the ACA, including potential changes thereto, to continue to significantly impact its business operations and operating results, including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

Medicare

The Company was granted approval by the Centers for Medicare and Medicaid Services to offer Medicare products in the State of Iowa, effective January 1, 2020.

The Company's Medicare Advantage products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, in the second quarter of 2014, CMS issued a final rule implementing the ACA requirements that Medicare Advantage plans report and refund to CMS overpayments that those plans receive from CMS. The precise interpretation, impact and legality of this rule are not clear and are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage business also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the U.S. Department of Justice, the Office of Inspector General of the HHS (the "OIG") and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of the Company's Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company's (and the industry's) participation in the Medicare program.

The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company's Medicare or Medicare-Medicaid demonstration (historically known as "dual eligible") plans, exclude the Company from participating in one or more Medicare, dual eligible or dual eligible special needs plan programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements.

Federal Employees Health Benefits Program

The Company contracts with the OPM to provide managed health care services under the FEHB program in its service areas. These contracts with the OPM and applicable government regulations establish premium rating arrangements for this program. OPM regulations require that community-rated FEHB plans meet a FEHB program-specific minimum MLR by plan code and market. Managing to these rules is complicated by the simultaneous application of the minimum MLR standards and associated premium rebate requirements of the ACA. The OPM also is auditing the Company and its other contractors to, among other things, verify that plans meet their applicable FEHB program-specific MLR and the premiums established under the OPM's Insured contracts and costs allocated pursuant to the OPM's cost-based contracts are in compliance with the requirements of the applicable FEHB program. The OPM may seek premium refunds or institute other sanctions against the Company if the Company fails to comply with the FEHB program requirements.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2021 or 2020.
- E. The Company did not have any state transferable and non-transferable tax credits for the years ending December 31, 2021 or 2020.
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2021 or 2020.
- G. The Company did not have any retained assets at December 31, 2021 or 2020.
- H. The Company did not have any insurance-linked securities contracts at December 31, 2021 or 2020.
- I. The Company did not have amounts that could be realized on life insurance at December 31, 2021 or 2020.

22. Events Subsequent

Type I - Recognized Subsequent Events

Subsequent events have been considered through February 24, 2022 for the statutory statement issued on February 25, 2022.

The Company had no known reportable recognized subsequent events.

Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 24, 2022 for the statutory statement issued on February 25, 2022.

The Company had no known reportable nonrecognized subsequent events.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes () No (X)

If yes, give full details. N/A

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

If yes, give full details. N/A

Section 2 – Ceded Reinsurance Report – Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?

Yes () No (X)

- a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate. N/A
- b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement? N/A
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details. N/A

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. N/A
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes () No (X)

If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? $N\!/\!A$

- B. The Company did not have uncollectible reinsurance at December 31, 2021 or 2020.
- C. The Company did not have any commutation of ceded reinsurance at December 31, 2021 or 2020.
- D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2021 or 2020.
- E. The Company had no reinsurance contracts to which the reinsurance credit disclosure applies at December 31, 2021.
- 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination
 - A. Through annual contracts with CMS, the Company's Medicare Advantage revenues ultimately received for each member are based on that member's health status and demographic characteristics, as determined via the CMS risk adjustment process, under which the Company regularly submits risk adjustment data to CMS. Under the risk adjustment process, the Company records a receivable for future revenues that it expects to receive from CMS in the following year, after the final reconciliation of risk adjustment data for the current contract year is complete. These amounts are recognized in the current year as premiums under contracts subject to redetermination. In addition, the Company's Medicare Advantage contracts are subject to retrospective rating provisions under which the Company and CMS share in amounts above and below agreed-upon target medical benefit ratios.

Premium revenue subject to the minimum MLR rebate requirements of the ACA is recorded net of the estimated minimum MLR rebates for the current calendar year. The Company estimates the minimum MLR rebates by projecting MLRs for certain markets, as defined by the ACA, for each state in which the Company operates. The claims and premiums used in estimating such rebates are modified for certain adjustments allowed by the ACA and include a statistical credibility adjustment for those states with a number of members that is not statistically credible.

- B. Accrued retrospective are recorded as an adjustment to earned premiums and are estimated based on calculations that compare the Company's expected financial results for the contract against the appropriate medical benefit ratio target.
- C. Contracts Subject to Retrospective Rating Features

The Company had net premiums written of \$43,676,966 that were subject to retrospective rating features for the year ending December 31, 2021 representing 100.0% of total net premiums written.

D. Medical loss ratio rebates required pursuant to the Public Health Service Act

		1 Individual	2 Small Group Employer	3 Large Group Employer	4 Other Categories with rebates	5 Total
Prior	Reporting Year					
(1)	Medical Loss Ratio Rebates Incurred	\$	\$	\$ 459,404	\$	\$ 459,404
(2)	Medical Loss Ratio Rebates Paid	_	_	_	_	—
(3)	Medical Loss Ratio Rebates Unpaid	_	_	5,053,443	—	5,053,443
(4)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(5)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(6)	Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	5,053,443
Curre	ent Reporting Year-to-Date					
(1)	Medical Loss Ratio Rebates Incurred	\$	\$	\$ 505,344	\$ —	\$ 505,344
(2)	Medical Loss Ratio Rebates Paid	_	_	—	—	—
(3)	Medical Loss Ratio Rebates Unpaid	—	—	5,558,787	—	5,558,787
(4)	Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(5)	Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(6)	Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	5,558,787

- E. Risk Sharing Provisions of the Affordable Care Act ("ACA")
 - (1) Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? Yes [X] No []
 - (2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year:

		AMOUNT
a.	Permanent ACA Risk Adjustment Program	
	Assets	
	1. Premium adjustments receivable due to ACA Risk Adjustment	\$ 1
	Liabilities (including high-risk pool payments)	
	2. Risk adjustment user fees payable for ACA Risk Adjustment	27
	3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool payments)	31,186
	Operations (Revenue & Expense)	
	4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	110,604
	5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	299
b.	Transitional ACA Reinsurance Program	
	Assets	
	1. Amounts recoverable for claims paid due to ACA Reinsurance	_
	2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	—
	3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	
	Liabilities	
	4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	
	5. Ceded reinsurance premiums payable due to ACA Reinsurance	
	6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance	
	Operations (Revenue & Expense)	
	7. Ceded reinsurance premiums due to ACA Reinsurance	
	8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	_
	9. ACA Reinsurance contributions - not reported as ceded premium	_
c.	Temporary ACA Risk Corridors Program	
	Assets	
	1. Accrued retrospective premium due to ACA Risk Corridors	_
	Liabilities	
	2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	_
	Operations (Revenue & Expense)	
	3. Effect of ACA Risk Corridors on net premium income (paid/received)	_
	4. Effect of ACA Risk Corridors on change in reserves for rate credits	—

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance:

	Accrued During on Busine	g the Prior Year ss Written	Received or Current Yea	Paid as of the r on Business	Diffe	rences	А	djustments		Unsettled Bal Report	ances as of the ing Date
		nber 31 of the Year		e December 31 rior Year	Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. Permanent ACA Risk Adjustment Program											
1. Premium adjustments receivable (including high-risk)	\$ 107,033	s —	\$ 248,726	\$	\$ (141,693)	\$	\$ 141,694	s —	А	\$ 1	\$
2. Premium adjustments (payable) (including high-risk pool payments)	_	2,134	_	2,038	_	96	_	(96)	в	_	_
3. Subtotal ACA Permanent Risk Adjustment Program	107,033	2,134	248,726	2,038	(141,693)	96	141,694	(96)		1	_
b. Transitional ACA Reinsurance Program											
1. Amounts recoverable for claims paid	_	—	—	_	—	_	_	—	С	_	_
2. Amounts recoverable for claims unpaid (contra liability)	_	—	—	_	—	_	_	_	D	_	_
3. Amounts receivable relating to uninsured plans	_	_	—	_	—	_	_	_	Е	_	_
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	_	_	_	_	_	_	_	_	F	_	_
5. Ceded reinsurance premiums payable	_	—	—	_	—	_	—	—	G	_	_
6. Liability for amounts held under uninsured plans	_	_	—	_	—	_	_	_	Н	_	_
7. Subtotal ACA Transitional Reinsurance Program	_	_	_	_	_	_	_	_		_	_
c. Temporary ACA Risk Corridors Program											
1. Accrued retrospective premium	-	_	—	-	_	—	_	_	Ι		-
2. Reserve for rate credits or policy experience rating refunds	_	_	—	_	—	_	_	_	J	_	_
3. Subtotal ACA Risk Corridors Program	_	_	—	_	—	_	_	_		_	_
d. Total for ACA Risk Sharing Provisions	\$ 107,033	\$ 2,134	\$ 248,726	\$ 2,038	(\$141,693)	\$ 96	\$ 141,694	\$ (96)		\$ 1	s —
Explanations of Adjustments A. Due to updates to the data B. C. D.	a available to	the Compan	y to calculat	te the risk ad	justment.	-		·`		-	-

E. F. G. H. I. J.

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year:

Risk Corridors Program Year	Accrued on	Durin; Busine	g the Priess Writte	or Year en	Received or Paid as of the Current Year on Business		Diffe	rences			A	ljustments	_	Ur	Unsettled Balances as of the Reporting Date				
	Before	Before December 31 of the Prior Year		Written Before December 31 of the Prior Year		Prior Year Accrued Less Payments (Col 1 - 3) (Col 2 - 4)			ior Year ances	To Prior Yea Balances	r	Bala	nulative nce from Years (Col 3 + 7)	E Pri	Cumulative Balance from or Years (Col 2 - 4 + 8)				
	1		1	2		3		4	5		6		7	8			9		10
	Receiv	able	(Pay	able)	Rece	ivable	(Pay	able)	Receivable	(Pa	ayable)	Rece	eivable	(Payable)	Ref	Ree	eivable		(Payable)
a. 2014																			
1. Accrued retrospective premium	\$	_	\$	_	\$	_	\$	—	\$—	\$	_	\$	—	\$ -	- A	\$	_	\$	_
2. Reserve for rate credits or policy experience rating refunds		_		_		_		_	_		_		_	_	- В		_		_
b. 2015																			
1. Accrued retrospective premium		_		—		_		—	_		—		—	_	- C		_		—
2. Reserve for rate credits or policy experience rating refunds		_		_		_		_	_		_		_	_	- D		_		_
c. 2016																			
1. Accrued retrospective premium		_		—		_		—	_		—		—	_	- E		_		—
2. Reserve for rate credits or policy experience rating refunds		_		_		_		_	_		_		_	_	- F		_		_
d. Total for Risk Corridors	\$	_	\$	—	\$	_	\$	—	\$—	\$	—	\$	—	\$ -	-	\$		\$	_

24E(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

Explanations of Adjustments

А. В.

C. D. E.

E. F.

(5) ACA Risk Corridors Receivable as of Reporting Date:

	Risk Corridors Program Year	1 Estimated Amount to be Filed or Final Amount Filed with CMS	2 Non-Accrued Amounts for Impairment or Other Reasons	3 Amounts received from CMS	4 Asset Balance (Gross of Non- admissions) (1-2-3)	5 Non-admitted Amount	6 Net Admitted Asset (4-5)
a.	2014	\$ 2,707,708	\$ —	\$ 2,707,708	\$ —	\$	\$ —
b.	2015	705,180	_	705,180	_	_	_
c.	2016	1,370,536	_	1,370,536	_	_	_
d.	Total $(a + b + c)$	\$ 4,783,424	\$ —	\$ 4,783,424	\$ —	\$ —	\$

24E(5)d (Column 4) should equal 24E(3)c1 (Column 9) 24E(5)d (Column 6) should equal 24E(2)c1

25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2021 and 2020.

	 2021	2020
Balance, January 1	\$ 4,100,125 \$	3,627,903
Health care receivable	 (457,115)	(34,818)
Balance, January 1, net of health care receivable	3,643,010	3,593,085
Incurred related to:		
Current year	37,727,212	22,452,452
Prior years	 (2,390,844)	(3,364,734)
Total incurred	35,336,368	19,087,718
Paid related to:		
Current year	33,557,943	18,821,130
Prior years	 1,655,426	216,663
Total paid	35,213,369	19,037,793
Balance, December 31, net of health care receivable	3,766,009	3,643,010
Health care receivable	 746,490	457,115
Balance, December 31	\$ 4,512,499 \$	4,100,125

- A. Reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by \$2,390,844 in 2021 and \$3,364,734 in 2020. Changes in prior periods' estimates represents the effect of favorable development of prior period health care cost estimates on current year net income, at each financial statement date. The favorable development of these reserves is primarily a result of the actual claim submission times for health care claims being shorter than the Company had anticipated, as well as lower than expected health care cost trends in determining claims unpaid at prior financial statement date for both 2021 and 2020. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.
- B. There has been no significant change in the Company's methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2021 or 2020.

27. Structured Settlements

The Company did not have any structured settlements at December 31, 2021 or 2020.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with pharmaceutical companies for rebates, which cover the Company's membership as well as the membership of other affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At December 31, 2021 and 2020, the Company had pharmaceutical rebate receivables of \$639,648 and \$389,916, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing		Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2021	\$ 1,763,303	\$ —	\$ 1,123,357	1	\$ —	\$ —
9/30/2021	1,665,106	1,653,844	1,654,048		_	—
6/30/2021	1,484,317	1,487,475	1,487,524		_	—
3/31/2021	1,283,282	1,307,287	1,307,332		_	_
12/31/2020	1,064,287	1,071,288	1,071,288		_	—
9/30/2020	966,772	987,362	987,362		_	—
6/30/2020	863,578	895,289	895,289		_	—
3/31/2020	567,696	595,703	595,703		_	—
12/31/2019	36,071	38,057	38,057		_	_
9/30/2019	66,085	60,177	60,177		_	
6/30/2019	87,942	75,303	75,303		_	_
3/31/2019	93,178	65,385	65,385		—	_

¹ Represents a portion of the estimated rebates for the quarter ending December 31, 2021, which were paid by AHM to the Company prior to December 31, 2021 and invoicing in 2022.

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2021 or 2020.

Other receivables

Pharmacy Direct and Indirect Remuneration ("DIR") Generic

The Company receives retrospective generic performance network rebates ("PNR") on its Medicare business through an agreement with AHM. AHM has contractual agreements with network pharmacies for PNR. The PNR is performance based upon whether the participating pharmacies have met certain pre-established rates specified in the contract. The PNR is calculated by multiplying the applicable claims with a variable network rate based on the actual performance. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - *Health Care and Government Insured Plan Receivables*.

Pharmacy DIR Brand

The Company receives retrospective brand PNR on its Medicare business through an agreement with AHM. As mentioned above, AHM has contractual agreements with network pharmacies for PNR. The program collects varying percentages of brand ingredient cost from pharmacies, depending how well they perform on adherence measures, including stars-related measures. The PNR agreement for 2020 has three performance measurement periods ending April 30, August 31 and December 31, respectively. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - *Health Care and Government Insured Plan Receivables*.

29. Participating Policies

The Company did not have any participating policies at December 31, 2021 or 2020.

30. Premium Deficiency Reserves

	December 31, 2021
1. Liability carried for premium deficiency reserves	\$—
2. Date of the most recent evaluation of this liability	12/31/2021
3. Was anticipated investment income utilized in the calculation?	Yes 🗆 No 🗹

31. Anticipated Salvage and Subrogation

The Company did not reduce its liability for unpaid claims/losses by any estimated anticipated salvage and subrogation at December 31, 2021 or 2020 as the Company records salvage and subrogation on a paid basis when cash is received.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

GENERAL

	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.			Yes [X] No []
1.2	If yes, did the reporting entity register and file with its domiciliary State Insuch regulatory official of the state of domicile of the principal insurer in t providing disclosure substantially similar to the standards adopted by the its Model Insurance Holding Company System Regulatory Act and mode subject to standards and disclosure requirements substantially similar to	e Holding Company System, a regi National Association of Insurance C regulations pertaining thereto, or is	stration statement Commissioners (NAIC) in the reporting entity	s [X] No [] N/A []
1.3	State Regulating?			low	a
1.4	Is the reporting entity publicly traded or a member of a publicly traded gro	up?		Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code is:	ued by the SEC for the entity/group		000006	4803
2.1	Has any change been made during the year of this statement in the char reporting entity?	er, by-laws, articles of incorporation	, or deed of settlement of the] No []
2.2	If yes, date of change:				2021
3.1	State as of what date the latest financial examination of the reporting ent				
				12/31/	2020
3.2	State the as of date that the latest financial examination report became a entity. This date should be the date of the examined balance sheet and r			12/31/	2015
3.3	State as of what date the latest financial examination report became ava domicile or the reporting entity. This is the release date or completion da examination (balance sheet date).	e of the examination report and not	the date of the	07/06/	2017
3.4	By what department or departments? Iowa Insurance Division				
3.5	Have all financial statement adjustments within the latest financial exami statement filed with Departments?			s [] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination r	eport been complied with?	Үе	s [] No [] N/A [X]
4.1 4.2	4.12 renew During the period covered by this statement, did any sales/service organ receive credit or commissions for or control a substantial part (more than	es of the reporting entity), receive cr asured on direct premiums) of: of new business? als? zation owned in whole or in part by t	edit or commissions for or con	Yes [Yes [] No [X]] No [X]
		of new business?als?] No[X]] No[X]
5.1	Has the reporting entity been a party to a merger or consolidation during If yes, complete and file the merger history data file with the NAIC.			-	
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of ceased to exist as a result of the merger or consolidation.	domicile (use two letter state abbrev	viation) for any entity that has		
	1 Name of Entity	2 NAIC Company Code	3 State of Domicile		
6.1	Has the reporting entity had any Certificates of Authority, licenses or regi revoked by any governmental entity during the reporting period?	trations (including corporate registr	ation, if applicable) suspended] No [X]
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly	control 10% or more of the reportir	ig entity?	Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control;			r	0.0 %
	7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the e attorney-in-fact; and identify the type of entity(s) (e.g., individual, co	ntity is a mutual or reciprocal, the na	ationality of its manager or		
	1 Nationality	2 Type of E			

GENERAL INTERROGATORIES

8.1 8.2	Is the company a subsidiary of a depository institution holding company If the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No	[X]]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fin If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the 0 Insurance Corporation (FDIC) and the Securities Exchange Commission	ms? (city and state of the main office) of any affiliates rr Office of the Comptroller of the Currency (OCC), th	egulated ie Feder	by a feo al Depo	deral	Yes []	No	[X]]
	1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC				
8.5	Is the reporting entity a depository institution holding company with sign Federal Reserve System or a subsidiary of the reporting entity?					Yes []	No	[X]]
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiary of Federal Reserve Board's capital rule?				/oc [] No [¥ 1	N/	Δſ	1
9.	What is the name and address of the independent certified public account	untant or accounting firm retained to conduct the a	nnual au	ıdit?] 110 [Λ.	147	~ [1
10.1	Ernst & Young LLP; 200 Clarendon Street; Boston, MA 02116 Has the insurer been granted any exemptions to the prohibited non-auc	dit services provided by the certified independent p	ublic aco	countant	t					
	requirements as allowed in Section 7H of the Annual Financial Reportir law or regulation?	ng Model Regulation (Model Audit Rule), or substa	ntially si	nilar sta	ite	Yes []	No	[X]]
10.2	If the response to 10.1 is yes, provide information related to this exemp									
10.3 10.4	Has the insurer been granted any exemptions related to the other requi allowed for in Section 18A of the Model Regulation, or substantially sim If the response to 10.3 is yes, provide information related to this exemp	rements of the Annual Financial Reporting Model I ilar state law or regulation?	Regulatio	on as		Yes []	No	[X]]
10.4										
10.5	Has the reporting entity established an Audit Committee in compliance	with the domiciliary state insurance laws?		Y	/es [X	[] No []	N/	Ά[]
10.6	If the response to 10.5 is no or n/a, please explain									
11.	What is the name, address and affiliation (officer/employee of the repor firm) of the individual providing the statement of actuarial opinion/certifi Jeffrey J.Drzazgowski, F.S.A., M.A.A.A.; CVS; 151 Farmington Ave., R	ting entity or actuary/consultant associated with ar cation?	actuaria	al consu	lting					
12.1						Yes []	No	[X]	
	12.11 Name of real e	state holding company								
		cels involved								•
12.2	If, yes provide explanation: 12.13 Total book/adju	usted carrying value				.\$				0
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIE									
13.1	What changes have been made during the year in the United States many N/A									
13.2	1 5	, ,				•	-	No]
13.3	Have there been any changes made to any of the trust indentures durin						-]
13.4 14.1	If answer to (13.3) is yes, has the domiciliary or entry state approved the Are the senior officers (principal executive officer, principal financial offi] No [N/	ΑĮ	1
	 a. Honest and ethical conduct, including the ethical handling of actual or relationships; 	ch includes the following standards?				Yes [)	(]	No	[]]
	b. Full, fair, accurate, timely and understandable disclosure in the period		ty;							
	c. Compliance with applicable governmental laws, rules and regulationsd. The prompt internal reporting of violations to an appropriate person of	,								
1/11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:									
17.11										
	Has the code of ethics for senior managers been amended?					Yes [)	(]	No	[]]
14.21	If the response to 14.2 is yes, provide information related to amendmen The "Maintaining Trust" section that contained Corporate Integrity Agree		avnired							
	The index was removed.		•							
	Annual benchmarking exercise performed resulting in the following upd addition of accessibility channels, colleague intro letter, Diversity and In throughout etc.	clusion, MGE, Social Media, misc. definitions and	revision	S						
14.3	throughout, etc. Have any provisions of the code of ethics been waived for any of the sp					Yes []	No	[X]]
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).					-	-		-	

GENERAL INTERROGATORIES

] No [X	[]
	1 American Bankers Association (ABA) Routing	2		3		4	
	Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit	Am	iount	
		BOARD O		S			
16.		or sale of all investments of the reporting entity passed upon	either by the board of	of directors or a subordinate committee	Yes [X] No []
17.	Does the report	ing entity keep a complete permanent record of the proceedir	ngs of its board of dir	ectors and all subordinate committees] No []
18.] No []
			ANCIAL				
19.	Accounting Prin	ent been prepared using a basis of accounting other than Sta priples)?			Yes [] No [X	(]
20.1	Total amount lo	aned during the year (inclusive of Separate Accounts, exclus	ve of policy loans):	20.11 To directors or other officers	\$		0
				20.12 To stockholders not officers	\$		0
				20.13 Trustees, supreme or grand			
00.0	Tatal and a state of			(Fraternal Only)	\$		0
20.2	policy loans):	f loans outstanding at the end of year (inclusive of Separate A	ccounts, exclusive o	20.21 To directors or other officers	\$		0
	policy loans).			20.22 To stockholders not officers			
				20.23 Trustees, supreme or grand (Fraternal Only)			
21.1	Were any asset	is reported in this statement subject to a contractual obligation reported in the statement?	n to transfer to anoth	er party without the liability for such			
21.2	If yes, state the	amount thereof at December 31 of the current year:		21.21 Rented from others.			
				21.22 Borrowed from others.			
				21.23 Leased from others	\$		0
				21.24 Other	\$		0
22.1	guaranty associ	ment include payments for assessments as described in the A ation assessments?		tructions other than guaranty fund or	Yes [X] No []
22.2	If answer is yes			2.21 Amount paid as losses or risk adjustmeni 2.22 Amount paid as expenses			
				2.23 Other amounts paid			
23.1		ing entity report any amounts due from parent, subsidiaries o					
23.2		any amounts receivable from parent included in the Page 2 ar			\$		0
24.1	90 days?	er utilize third parties to pay agent commissions in which the a			Yes [] No [X	[]
24.2	If the response	to 24.1 is yes, identify the third-party that pays the agents and	I whether they are a	related party.			
			Is the				
			Third-Party Age				
		Name of Third-Party	a Related Par (Yes/No)	ιy			
			(

INVESTMENT

GENERAL INTERROGATORIES

25.02 If no, give full and complete information relating thereto

25.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided) N/A

25.04	For the reporting entity's securities lending program, report amount of colla Instructions.	ateral for conforming programs as outlined in the Risk-Based	Capital	i		(0
25.05	For the reporting entity's securities lending program, report amount of colla	ateral for other programs.	9			(0
25.06	Does your securities lending program require 102% (domestic securities) a outset of the contract?		Yes [] No [] N	/A [X]
25.07	Does the reporting entity non-admit when the collateral received from the c	counterparty falls below 100%?	Yes [] No [] N	/A [X]
25.08	Does the reporting entity or the reporting entity 's securities lending agent is conduct securities lending?		Yes [] No [] N	/A [X]
25.09	For the reporting entity's securities lending program state the amount of the	ne following as of December 31 of the current year:					
	25.091 Total fair value of reinvested collateral assets repo	orted on Schedule DL, Parts 1 and 2.	\$				0
	25.092 Total book adjusted/carrying value of reinvested co	collateral assets reported on Schedule DL, Parts 1 and 2	\$				Û
	25.093 Total payable for securities lending reported on the	e liability page.	\$				0
26.1	Were any of the stocks, bonds or other assets of the reporting entity owner control of the reporting entity, or has the reporting entity sold or transferred force? (Exclude securities subject to Interrogatory 21.1 and 25.03).	any assets subject to a put option contract that is currently i	n	Yes [] No	[X]	
26.2	If yes, state the amount thereof at December 31 of the current year:	26.21 Subject to repurchase agreements		5			0
		26.22 Subject to reverse repurchase agreements		5		!	0
		26.23 Subject to dollar repurchase agreements		5		!	0
		26.24 Subject to reverse dollar repurchase agreen					
		26.25 Placed under option agreements		5		!	0
		26.26 Letter stock or securities restricted as to sale	e -				_
			° ,				
		excluding FHLB Capital Stock	5	5			0
		excluding FHLB Capital Stock 26.27 FHLB Capital Stock		5		!	0
		excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states		5 5			0.0
		excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies		5 5 5			0.0
		excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies		5 5 5			0.0
		excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states	oledged to	5 5 5 6			0.0

26.3 For category (26.26) provide the following:

	1 Nature of Restriction	2 Description		3 iount		
27.1	Does the reporting entity have any hedging transactions reported on Sc	hedule DB?	Yes [] No	o [X]
27.2	If yes, has a comprehensive description of the hedging program been m If no, attach a description with this statement.	hade available to the domiciliary state? Yes [] No [] [N/A [X]
LINES 2	7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONL	Y:				
27.3	Does the reporting entity utilize derivatives to hedge variable annuity gu	arantees subject to fluctuations as a result of interest rate sensitivity?	Yes [] No	o [X]
27.4	27.42 Per	cial accounting provision of SSAP No. 108 mitted accounting practice er accounting guidance	Yes [] No] No] No	0[]]]
27.5	By responding YES to 27.41 regarding utilizing the special accounting p following: • The reporting entity has obtained explicit approval from the dor • Hedging strategy subject to the special accounting provisions is	niciliary state.	Yes [] No	0[]
	 Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within Financial Officer Certification has been obtained which indicates 	he hedging strategy is incorporated within the establishment of VM-21				
28.1	Were any preferred stocks or bonds owned as of December 31 of the c issuer, convertible into equity?		Yes [] No	o [X]
28.2	If yes, state the amount thereof at December 31 of the current year		\$			0
29.	Excluding items in Schedule E - Part 3 - Special Deposits, real estate, r offices, vaults or safety deposit boxes, were all stocks, bonds and other custodial agreement with a qualified bank or trust company in accordan Outsourcing of Critical Functions, Custodial or Safekeeping Agreement	securities, owned throughout the current year held pursuant to a ce with Section 1, III - General Examination Considerations, F.	Yes [)	X]N(o []

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1	2
Name of Custodian(s)	Custodian's Address
State Street Bank and Trust Company	State Street Financial Center; One Lincoln Street; Boston, MA 02111-2900

GENERAL INTERROGATORIES

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2	l
Name of Firm or Individual	Affiliation	I
Derek S. Blunt as Senior Investment Officer	Α	

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
N/A	Derek S. Blunt	N/A	Not registered	NO
			-	

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? 30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP #	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	21,246,056		1,056,436
31.2 Preferred stocks	0	0	0
31.3 Totals	21,246,056	22,302,492	1,056,436

31.4 Describe the sources or methods utilized in determining the fair values:

	Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short Term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.				
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes []	No [X]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes []	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:				
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? If no, list exceptions:	Yes []	X]	No []
34.	 By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. 				
	Has the reporting entity self-designated 5GI securities?	Yes []	No [X]
35.	 By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities? 	Yes []	No [X]
36.	 By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? 	Yes []	No [X]
37.	 By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. 				

a. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a -37.c are reported as long-term investments.

Has the reporting entity roll	ed/renewed short-term or cash equivalent investments in accordance with these criteria?	Yes [X]	No [] [N/A []

GENERAL INTERROGATORIES

OTHER

38.1	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?	\$	0
38.2	List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to t service organizations and statistical or rating bureaus during the period covered by this statement.	ade associations,	
	1 2 Name Amount Paie	1	
39.1	Amount of payments for legal expenses, if any?	\$	0
39.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal exp during the period covered by this statement.	enses	
	1 2 Name Amount Paie		
40.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of governme	nt, if any?\$	0
40.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures connection with matters before legislative bodies, officers or departments of government during the period covered by this state		

1	2
Name	Amount Paid

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2	Does the reporting entity have any direct Medicare Supplement Insurance in force? If yes, indicate premium earned on U.S. business only		.\$0
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance E. 1.31 Reason for excluding		\$0
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien not	included in Item (1.2) above	.\$0
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.		
1.6	Individual policies:	Most current three years:	_
		1.61 Total premium earned	
		1.62 Total incurred claims	
		1.63 Number of covered lives	
		All years prior to most current three years:	
		1.64 Total premium earned 1.65 Total incurred claims	
		1.66 Number of covered lives	
1.7	Group policies:	Most current three years:	
		1.71 Total premium earned	\$0
		1.72 Total incurred claims	
		1.73 Number of covered lives	
		All years prior to most current three years:	
		1.74 Total premium earned	
		1.75 Total incurred claims	
		1.76 Number of covered lives	0
2.	Health Test:	1	
		1 2 Current Year Prior Year	
	2.1 Premium Numerator		
	2.2 Premium Denominator		
	2.3 Premium Ratio (2.1/2.2)		
	2.4 Reserve Numerator		
	2.5 Reserve Denominator		
	2.6 Reserve Ratio (2.4/2.5)		
3.2	If yes, give particulars:		
4.1	Have copies of all agreements stating the period and nature of hospitals', physician dependents been filed with the appropriate regulatory agency?	s', and dentists' care offered to subscribers and	Yes [X] No []
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these a	greements include additional benefits offered?	Yes [] No [X]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]
5.2	If no, explain: The company does not have any stop loss agreements.		
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	\$9,999.999
-	· · · · ·	5.32 Medical Only	
		5.33 Medicare Supplement	.\$0
		5.34 Dental & Vision	
		5.35 Other Limited Benefit Plan	
6.	Describe arrangement which the reporting entity may have to protect subscribers ar hold harmless provisions, conversion privileges with other carriers, agreements with		\$0
	agreements: Provider contracts contain hold harmless and continuity of coverage provisions		
7.1	Does the reporting entity set up its claim liability for provider services on a service d	ate basis?	Yes [X] No []
7.2	If no, give details		
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year .	
9.1	Does the reporting entity have business subject to premium rate guarantees?	8.2 Number of providers at end of reporting year	
9.1		8.2 Number of providers at end of reporting year	16,845 Yes [] No [X]

GENERAL INTERROGATORIES

40.5							Vec I V	
10.1	Does the reporting entity have Incentive Pool, Withh	hold or Bonus Arr	angements in its p	provider contracts?			res [X	J NO []
10.2	If yes:		1	0.21 Maximum amo	unt payable bonus	es	\$	
				0.22 Amount actual				
				0.23 Maximum amo				
			1	0.24 Amount actual	ly paid for year with	nholds	\$	0
11.1	Is the reporting entity organized as:							
11.1	is the reporting entity organized as.			11 12 A Medical	Group/Staff Mode	I	Yes [] No [X]
					ual Practice Assoc] No [X]
					Nodel (combination	(), ,	Yes [] No [X]
11.2	Is the reporting entity subject to Statutory Minimum						Yes [X	
11.3	If yes, show the name of the state requiring such mi							lowa 3,876,704
11.4 11.5	If yes, show the amount required. Is this amount included as part of a contingency resu] No [X]
11.6	If the amount is calculated, show the calculation		er s equity:				100 [] 10 [/]
	See Notes to Financial Statement - Note 21, Other I	Items, C., Other I	Disclosures					
12.	List service areas in which reporting entity is license	ed to operate:						
			1					
			Name of Service	e Area				
	License	covers entire St	ate of Iowa					
13.1	Do you act as a custodian for health savings accour	nts?					Yes [] No [X]
12.2	If yes, please provide the amount of custodial funds	hold on of the re	norting data				¢	0
13.2	if yes, please provide the amount of custodial funds	field as of the re	porting date				\$	0
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No [X]
							-	
13.4	If yes, please provide the balance of funds administe	ered as of the rep	oorting date				\$	0
111	Are any of the captive affiliates reported on Schedul	o S. Dort 2 outb	orized reineurora?			Vec I	1 No 1	
14.1 14.2	If the answer to 14.1 is yes, please provide the follow					tes [] NO [J NZA [X]
17.2		wing.						
	1	2	3	4		Supporting Reserve		
		NAIC Company	Domiciliary	Reserve	5 Letters of	6 Trust	7	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	-
				0	0	0		0
				0	0	0		0
<u></u>				-				
15.	Provide the following for individual ordinary life insur	rance* policies (I) for the current vea	r (prior to reinsurar	ace assumed or		
15.	ceded):	ance policies (c	J.G. Dusiness only) for the current yea		ice assumed of		
				15.1 Di	rect Premium Writ	ten	\$	0
				15.2 To	otal Incurred Claim	s	\$	0
				15.3 Ni	umber of Covered	Lives		0
	· · · · · · · · · · · · · · · · · · ·	*Ordin	any Life Incurance	Includes				
	Term(whether full und		ary Life Insurance d underwriting, iet		ממ")			
	Whole Life (whether f	0 ,	0,1	,				
	Variable Life (with or							
	Universal Life (with o Variable Universal Lif			antee)		_		
			L SCOULARY AURAL					

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes [] No [X]

		1 2021	2 2020	3 2019	4 2018	5 2017
	Balance Sheet (Pages 2 and 3)	2021	2020	2013	2010	2011
1.	Total admitted assets (Page 2, Line 28)	31 969 343	59 708 364	52 473 827	53 997 097	97 012 85
2.	Total liabilities (Page 3, Line 24)					
2. 3.	Statutory minimum capital and surplus requirement			1,571,646		
	Total capital and surplus (Page 3, Line 33)					
4.						
-	Income Statement (Page 4) Total revenues (Line 8)	40 170 000	21 060 471	E E40 0E4	21 010 000	000 641 60
5.	Total medical and hospital expenses (Line 18)					
6.						
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)	3,549,301	8,347,180	2,782,400	2,004,575	8,346,000
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	20,725	9,977,404	(344,887)	(29,502,607)	
	Risk-Based Capital Analysis					
14.	Total adjusted capital					
15.	Authorized control level risk-based capital	1,938,352	1,150,247		1, 155, 358	6,919,526
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	2,820	1,874	437		
17.	Total members months (Column 6, Line 7)			11,835	67,758	
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)					
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)			46.8		
20.	Cost containment expenses	1.3	1.3		1.2	1.4
21.	Other claims adjustment expenses	0.5	0.5	0.9	0.6	
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	8.2			10.1	
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 13, Col. 5)	1,655,653		3,805,195		
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	3,589,382	3,582,718	6,618,140		
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	(
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	(
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to					
	31 above.	0	0	0	0	(

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories ness Only 2 3 4 5 6 8 9 10 Federal Employees Life and Annuity Active Accident and Benefits Premiums & Property/ Casualty Total Program Premiums Columns 2 Through 8 Status Health Medicare Medicaid CHIP Title Other Deposit-Type Contracts States, etc. Premiums Title XVIII Title XIX Premiums (a) XXI nsideration 1 Alabama AI Ν 0 0 0 0 0 0 0 0 0 2. Alaska AK Ν 0 0 0 0 0 0 0 0 0 0 3. Arizona ΑZ Ν 0 0 0 0 0 0 0 0 4. Arkansas AR ..0 .0 .0 .0 .0 .0 0 0 N ..0 5. California CA ..0 ..0 .0 .0 ..0 .0 .0 .0 0. N 6. Colorado 0 .0 0 .0 0 0 со Ν 0 0 0 7. Connecticut СТ .0 .0 .0 .0 .0 .0 .0 .0 0. N 8. Delaware DE N 0 0 0 0 0 0 0 0 0 9. District of Columbia DC Ν 0 0 0 0 0 0 0 0 0 0 10. Florida FL Ν. .0 ..0 .0 .0 ..0 .0 .0 .0 .0 0 0 0 11. Georgia GA N ..0 .0 .0 .0 .0 12. ..0 .0 .0 .0 .0 .0 .0 .0 0. Hawaii HI ..N. 13. Idaho ID ..N. .0 .0 .0 .0 .0 .0 .0 .0 .0 14. Illinois 0 0 0 .0 0 .0 0 .0 0 IL N 15 Indiana IN ..N. ٥ ٥ ٥ .0 ٥ ٥ ٥ ٥ 0 621.395 225,698 16. lowa IA L 43,230,351 0 0 0 0 44.077.444 0 0 17. Kansas ĸs Ν 0 0 0 0 0 0 0 0 18. Kentucky KΥ N .0 ..0 .0 .0 ..0 .0 .0 .0 .0 19. Louisiana .0 .0 .0 .0 .0 .0 .0 .0 .0 LA N ME .0 20. Maine ..N .0 .0 .0 .0 .0 .0 .0 .0 21. Maryland MD 0 .0 0 .0 .0 .0 0 0 0 Ν 22 Massachusetts MA .N. 0 0 0 0 0 0 0 0 0 23 Michigan М Ν 0 0 0 0 0 0 0 0 0 0 24. Minnesota MN Ν .0 0 0 .0 0 0 .0 0 Mississippi 25. MS .0 .Ν. ..0 ..0 .0 .0 ..0 .0 ..0 .0 26 Missouri МО 0 .0 .0 .0 .0 .0 .0 0 0 Ν .0 .0 .0 27. Montana MT N .0 .0 .0 .0 .0 .0 28 Nebraska NE .0 .0 .0 .0 ..0 .0 .0 .0 .0 N 29. Nevada NV N 0 0 0 .0 0 0 0 0 0 30. New Hampshire NH Ν 0 0 0 0 0 0 0 0 0 0 31. New Jersey NJ N .0 ..0 .0 .0 ..0 .0 0 0 32. New Mexico ..0 ..0 .0 .0 .0 .0 .0 .0 0 NM .Ν. 33. New York NY ..0 ..0 .0 .0 ..0 .0 .0 .0 0. N. 34. North Carolina .0 0 .0 .0 NC N 0 .0 .0 0 0 35 North Dakota ND .0 ..0 .0 .0 .0 .0 .0 .0 0. N 36 Ohio ОН Ν 0 0 0 0 0 0 0 0 0 37. Oklahoma OK Ν 0 0 0 0 0 0 0 0 0 38. Oregon. OR Ν 0 0 0 0 0 0 0 0 0 39. Pennsylvania PA ..0 .0 .0 .0 .0 .0 0 0 N ..0 40. Rhode Island RI ..0 ..0 .0 .0 ..0 .0 .0 .0 0. ..N. South Carolina 41. 0 0 0 .0 0 0 SC Ν 0 0 0 42. South Dakota SD .0 .0 .0 .0 .0 .0 .0 .0 0. N Tennessee 43. ΤN N. 0 0 0 0 0 0 0 0 0 44. Texas τх Ν 0 0 0 0 0 0 0 0 0 45. Utah UT Ν. .0 ..0 .0 .0 ..0 .0 .0 .0 0 46. .0 0 0 0 Vermont VT ..0 .0 .0 .0 .0 N 47 Virginia ..0 .0 .0 .0 .0 .0 .0 .0 0. VA ..N. Washington 48. WA ..N. .0 .0 .0 .0 .0 .0 .0 .0 .0 49. West Virginia WV N 0 .0 0 .0 0 .0 .0 .0 0 50 Wisconsin \//I N. ٥ .0 .0 .0 ٥ ٥ ٥ ٥ 0 51. Wyoming WY Ν 0 0 0 0 0 0 0 0 0 American Samoa 0 52. AS Ν 0 0 0 0 0 0 0 0 53. Guam GU ..0 .0 .0 .0 N ..0 .0 .0 ..0 .0 54 Puerto Rico . .0 .0 .0 .0 .0 .0 .0 .0 .0 PR Ν. U.S. Virgin Islands 55. VI ..N .0 ..0 .0 .0 .0 .0 .0 .0 .0 56. Northern Mariana .0 .0 .0 .0 0. 0 MP N .0 .0 0 Islands 57. .0 .0 .0 .0 .0 .0 .0 .0 .0 Canada CAN Ν. 58. Aggregate Other OT XXX. .0 0 .0 .0 0 0 0 0 .0 Aliens 225,698 59 Subtotal XXX .621,395 43,230,351 .0 .0 .0 .0 .44,077,444 .0 60 Reporting Entity Contributions for Employee .0 XXX .0 .0 .0 **Benefit Plans** 0 0 ..0 .0 0 Totals (Direct Business) 621,395 43,230,351 225,698 44,077,444 61 0 0 0 0 0 XXX DETAILS OF WRITE-INS 58001 ххх 58002 XXX 58003 XXX. Summary of remaining write-ins for Line 58 from 58998 overflow page Totals (Lines 58001 through 58003 plus 58998)(Line 58 0 .0 ..0 .0 .0 .0 .0 0 XXX. .0 58999 ٥ 0 ٥ 0 0 above) XXX ٥ ٥

(a) Active Status Counts

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG

E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. N - None of the above - Not allowed to write business in the state.

R - Registered - Non-domiciled RRGs. Q - Qualified - Qualified or accredited reinsurer. 0


0

(b) Explanation of basis of allocation by states, premiums by state, etc lowa is a single state company therefore all premiums are lowa.

0

56

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP PART 1 - ORGANIZATIONAL CHART



This organizational chart reflects the insurance entity reporting system and identifies the relationship between the ultimate parent and all member insurers. The ultimate controlling company is a Fortune 7 company with numerous subsidiaries, the majority of which do not interact with the insurance entities. (1) Insurers/HMO's Percentages are rounded to the nearest whole percent and based on ownership of voting rights.


Double borders indicate entity has subsidiaries shown on the same page.

Bold borders indicate entity has subsidiaries shown on a separate page.

*1 Coram Clinical Trials, Inc. is also 25% owned by Aetna Life Insurance Company

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




40.1

*1 PHPSNE Parent Corporation is also 45% owned by third parties.
 *2 CVS Cabot Holdngs Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
 *3 CVS Shaw Holdngs Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
 *4 Omnicare, LLC is also owned by CVS Cabot Holdings Inc and CVS Shaw Holdngs Inc., each with 49.86% ownership.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rivai, Aetna's Nominee.

- *2 Aetna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Aetna's Nominee. *3 Indian Health Organisation Private Limited is 0.019857% owned by Aetna Global Benefits (Asia Pacific) and 99.980143% owned by Aetna Global Benefits (Singapore) PTE. LTD.
- *4 Virtual Home Health Care L.L.C. is also 51% owned by CBD Commercial Brokers LLC, Aetna's Nominee

*5 Health Care Management Co. Ltd. Is also 31% owned by Actna Global Benefits (Bermuda) Limited (1 share).
 *6 Actna Health Insurance (Thailand) Public Company Limited is also owned by Actna Global Benefits (Bermuda) Limited (1 share), Actna Health Holdings (Thailand) Limited (1 share), Actna Services (Thailand) Limited (1 share), Ms. Saifon Khongjitngam (1 share), and Mr. Buncha Tanphragorn (1 share)


*7 Aetna Holdings (Thailand) Limited is also 51% owned by Mr. Paiboon Sutantivorakoon plus Aetna Benefits (Bermuda) Limited owns 1 share.

*8 Minor Health Enterprise Co, Ltd is is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited

*9 Aetna Services (Thailand) Limited is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited and (1 share) owned by Aetna Global Holdings Limited


SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP






SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP



*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share). *2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources. *4 Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.

*5 Allina Health and Aetha Insurance Holding Company LLC is also 50% owned by Allina Health. *6 Sutter Health and Aetha Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.




SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART

* Aetna Capital Management, LLC owns 100% of the voting rights of Aetna Partners Diversified Fund, LLC ("APDF"). APDF is a fund of hedge funds and certain subsidiaries of CVS Health Group invest in this fund, which does not confer any managing or controlling ownership interests in APDF.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.

*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.

*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health System.

*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC. *7 Coram Clinical Trials, Inc. is also 75% owned by CVS Pharmacy, Inc.

*8 CVS Cabot Holdings Inc. is also .28% owned by Aetna Inc.

*9 CVS Shaw Holdings Inc. is also .28% owned by Aetna Inc.

*10 Remaining .28% owned by Aetna Inc. CVS Cabot Holdings Inc. and CVS Shaw Holdings Inc. each owning 49.86%.

ANNUAL STATEMENT FOR THE YEAR 2021 OF THE Aetna Health of Iowa Inc. OVERFLOW PAGE FOR WRITE-INS